background
extendedspectrum
blactam
commonli
includ
empir
antibiot
regimen
treatment
gramneg
infect
emerg
extend
spectrum
blactamas
esbl
produc
bacteria
pose
seriou
threat
continu
use
famili
antibiot
sinc
esbl
previous
uniformli
suscept
blactamas
inhibitor
eg
tazobactam
clavulan
acid
inhibitorblactam
combin
eg
piperacillintazobactam
advoc
potenti
therapeut
effect
agent
method
june
clinic
isol
escherichia
coli
recov
woman
nurs
high
depend
surgic
ward
st
jame
univers
hospit
leed
uk
patient
receiv
cours
ceftazidim
piperacillin
tazobactam
piptaz
organ
isol
urin
specimen
speciat
confirm
biochem
api
system
organ
resist
ceftazidim
cefotaxim
aztreonam
piptaz
amoxicillinclavulan
acid
suscept
meropenem
imipenem
cefoxitin
use
disk
diffus
method
esbl
product
sought
use
disc
synergi
mast
id
test
pcr
use
specif
primer
use
screen
presenc
blashv
blatem
nucleotid
sequenc
analysi
use
determin
ident
resist
determin
result
esbl
product
demonstr
disc
synergi
mast
id
test
pcr
show
organ
harbour
blatem
nucleotid
sequenc
analysi
identifi
resist
determin
blactamas
addit
mutat
aminoacid
posit
replac
methionin
valin
mutat
previous
shown
confer
resist
betalactamas
inhibitor
conclus
knowledg
first
report
tem
extendedspectrum
blactamas
also
confer
resist
pip
taz
highlight
continu
global
emerg
mutabl
clinic
import
famili
enzym
emphasis
import
vigil
identifi
novel
resist
mechan
need
prudent
use
antimicrobi
preserv
clinic
efficaci
cephalosporin
ceftazidim
cefotaxim
blactamas
extract
ultrason
supernat
contain
crude
enzym
extract
analys
isoelectr
focus
ampholin
polyacrylamid
gel
ph
use
multiphor
ii
electrophoresi
system
pharmacia
biotech
blactamas
visualis
overlay
nitrocefin
previous
describ
primer
vebcasb
vebcasf
use
detect
gene
autom
dna
sequenc
perform
amplifi
product
primer
use
combin
respect
order
determin
size
variabl
region
integron
newli
design
primer
pveb
use
demonstr
colinear
integras
result
p
mirabili
strain
isol
urin
sampl
show
resist
extendedspectrum
cephalosporin
aminoglycosid
trimethoprimsulphamethoxazol
phosphomycin
unusu
synergi
observ
cefoxitin
cefotaxim
cefuroxim
use
doubledisc
synergi
isoelectr
focus
analysi
reveal
presenc
blactamas
pi
dna
sequenc
analysi
reveal
presenc
gene
show
ident
gene
found
p
mirabili
gene
cassett
locat
within
class
integron
approxim
kb
side
gene
two
unsequenc
region
around
bp
flank
integras
gene
upstream
segment
downstream
conclus
data
indic
gene
part
genet
environ
compris
class
integron
howev
variabl
region
integron
differ
size
previous
describ
integron
contain
gene
p
mirabili
e
coli
p
aeruginosa
studi
need
evalu
gene
cassett
codifi
variabl
region
paediatr
hospit
iasi
romania
sinc
preliminari
studi
undertaken
order
obtain
inform
epidemiolog
strain
mechan
resist
method
random
sampl
eight
e
coli
strain
isol
period
examin
suscept
statu
variou
antimicrobi
agent
assess
use
mini
api
system
bio
merieux
detect
extend
spectrum
blactamas
esbl
perform
etest
method
use
strip
contain
ceftazidim
plu
clavulan
acid
isoelectr
point
blactamas
produc
strain
determin
isoelectr
focus
ief
crude
cell
extract
type
strain
carri
pcrbase
method
use
oligonucleotid
primer
result
strain
show
resist
amoxicillin
amoxicillin
clavulan
acid
ceftazidim
cefoxitin
seven
cefoxitinresist
strain
esbl
detect
test
neg
upon
ief
strain
found
produc
blactamas
highli
basic
isoelectr
point
therefor
presum
strain
produc
acquir
ampc
enzym
remain
isol
ceftazidim
mic
significantli
reduc
presenc
clavulan
acid
strain
express
blactamas
focus
probabl
enzym
pcr
type
show
least
four
differ
band
pattern
suggest
widespread
resist
mechan
distinct
strain
conclus
frequent
isol
e
coli
paediatr
hospit
iasi
due
dissemin
epidemiolog
distinct
strain
resist
attribut
product
variou
blactamas
type
includ
ampc
cephalosporinas
extendedspectrum
enzym
reduct
use
gc
enforc
infect
control
measur
must
appli
object
two
clinic
unrel
pseudomona
aeruginosa
strain
isol
hospitalis
patient
brasilia
sao
paulo
respect
isol
express
class
b
carbapenemhydrolys
metalloblactamas
mbl
gene
found
embed
class
integron
also
encod
aminoglycosidemodifi
enzym
aim
studi
character
two
novel
aminoglycosid
resist
gene
arg
method
primer
target
region
class
integron
use
amplifi
contain
integron
primer
yield
pcr
product
sequenc
strand
use
dupont
autom
system
integron
sequenc
analysi
arg
amplifi
pcr
clone
express
vector
ppcrscriptcam
sk
recombin
plasmid
transfer
escherichia
coli
respect
aminoglycosid
resist
profil
evalu
gentamicin
amikacin
kanamycin
neomycin
netilmicin
sisomicin
isepamicin
tobramycin
nucleotid
sequenc
deduc
protein
product
align
phylogenet
relationship
determin
use
lasergen
softwar
packag
result
sequenc
analysi
reveal
presenc
two
novel
aminoglycosid
gene
downstream
name
aaca
aaca
respect
aaca
fuse
follow
gene
aaca
ib
form
open
read
frame
bp
potenti
encod
protein
kda
aac
possess
similar
previous
describ
aac
aaca
long
encod
put
protein
kda
similar
aaca
ib
found
carri
integron
strain
e
coli
strain
harbour
fuse
form
aac
ib
aaca
show
mic
three
fivefoldhigh
recipi
e
coli
strain
includ
gentamicin
amikacin
mic
remain
unalt
isepamicin
conclus
fuse
form
aac
ib
like
bifunct
protein
rather
express
aac
aac
ib
aac
ib
aac
confer
resist
profil
call
aac
iv
phenotyp
associ
mobil
mbl
gene
arg
present
immens
concern
sinc
enzym
neutralis
clinic
avail
inhibitor
besier
ludwig
v
brade
ta
wichelhau
frankfurt
main
object
antibiot
resist
due
chromosom
mutat
caus
structur
modif
cellular
target
drug
often
associ
fit
burden
resist
bacteria
loss
biolog
fit
howev
overcom
case
acquisit
compensatori
mutat
shown
recent
certain
amino
acid
exchang
elong
factor
g
efg
staphylococcu
aureu
caus
resist
fusid
acid
interestingli
fusid
acidresist
clinic
aureu
isol
carri
exchang
frequent
harbour
addit
amino
acid
substitut
within
efg
eg
contribut
resist
aim
present
studi
analys
biolog
cost
mutat
ii
investig
whether
mutat
abl
compens
fit
burden
method
influenc
amino
acid
exchang
within
efg
biolog
fit
aureu
analys
measur
growth
kinet
mean
fit
assay
plasmacoagulas
activ
assay
use
isogen
recombin
aureu
strain
carri
either
wildtyp
efg
gene
fusa
mutant
fusa
deriv
multicopi
plasmid
assay
start
defin
cell
number
bacteria
repeat
three
time
ensur
reproduc
result
assay
show
fusid
acid
resistancemedi
mutat
caus
mark
impair
biolog
fit
amino
acid
exchang
howev
influenc
fusid
acid
suscept
impair
biolog
fit
bacteria
slightli
present
individu
strain
express
efg
deriv
doubl
mutat
howev
grew
significantli
faster
show
enhanc
fit
competit
wildtyp
exhibit
higher
plasmacoagulas
activ
strain
harbour
singl
exchang
conclus
present
data
provid
evid
amino
acid
exchang
efg
function
fitnesscompens
mutat
fusid
acidresist
aureu
harbour
efg
mutat
therebi
demonstr
biolog
cost
fusid
acid
resist
aureu
consider
reduc
secondari
mutat
within
bacteri
genom
object
recent
describ
fourth
type
mobil
mbl
primari
studi
show
embed
class
integron
unusu
size
structur
aim
studi
characteris
genet
environ
method
integron
structur
reveal
walk
sequenc
strategi
use
custom
primer
sequenc
fragment
perform
strand
use
dupont
autom
system
result
analys
use
dnastar
plasmid
obtain
isol
harbour
electropor
escherichia
coli
rifampinresist
mutant
pseudomona
aeruginosa
rifr
select
perform
nutrient
agar
plate
contain
lgml
ceftazidim
restrict
profil
plasmid
carri
differ
restrict
enzym
obtain
plasmid
size
result
integron
show
key
genet
compon
commonli
found
class
integron
integras
gene
promot
region
recombin
site
fuse
structur
integron
harbour
first
posit
recent
describ
downstream
mbl
gene
found
follow
howev
second
aminoglycosid
resist
gene
interrupt
insert
sequenc
previous
describ
pseudomona
alcaligen
isol
integron
also
carri
esbl
gene
last
posit
two
frame
shift
found
integron
one
integras
gene
second
characteris
reveald
integron
like
locat
nontrasfer
plasmid
conclus
work
describ
novel
integron
carri
late
mobil
mbl
gene
describ
distinct
featur
interrupt
frame
shift
make
integras
insert
sequenc
stationari
argu
signific
decreas
activ
antimicrobi
agent
test
high
inocula
may
predict
possibl
therapeut
failur
case
sever
infect
aim
studi
determin
effect
larg
inocula
vitro
activ
amoxicillinclavulan
acid
amc
piperacillintazobactam
ptz
cefoperazonesulbactam
cp
escherichia
coli
klebsiella
pneumonia
strain
produc
variou
type
esbl
method
twenti
laboratori
strain
produc
know
esbl
esblproduc
clinic
isol
e
coli
n
k
pneumonia
n
collect
russian
hospit
includ
studi
esbl
product
detect
doubledisc
synergi
test
activ
amc
ptz
mgl
fix
tazobactam
concentr
cp
determin
broth
microdilut
test
use
standard
cfuml
higher
inocula
result
interpret
accord
current
nccl
guidelin
suscept
cp
determin
basi
cefoperazon
mic
breakpoint
result
test
standard
inocula
rate
resist
amc
ptz
cp
respect
data
mic
drug
test
differ
inocula
summaris
tabl
inoculum
effect
defin
eightfold
greater
mic
increas
test
higher
inoculum
commonli
observ
ptz
lessfrequ
detect
amc
cp
extent
inoculum
effect
drug
larg
independ
type
esbl
produc
highinoculum
test
two
strain
appear
resist
fep
ptz
wherea
strain
remain
suscept
amc
cp
respect
conclus
strong
inoculum
effect
detect
ptz
probabl
predict
high
risk
failur
drug
use
treatment
seriou
infect
caus
esblproduc
organ
base
lowest
resist
rate
least
pronounc
inoculum
effect
cp
may
consid
effect
blactamblactamas
inhibitor
combin
object
analysi
genet
context
mbl
contain
integron
carbapenem
resist
pseudomona
aeruginosa
strain
poland
germani
method
carbapenem
resist
strain
analys
ribotyp
pulsedfield
gel
electrophoresi
mblcontain
integron
strain
amplifi
use
primer
design
class
integron
specif
conserv
sequenc
cs
upstream
sequenc
amplifi
pcr
novel
degener
primer
approach
use
one
primer
anchor
cs
sequenc
degener
primer
design
randomli
hybridis
upstream
downstream
sequenc
sequenc
perform
strand
dideoxychain
termin
method
result
polish
isol
contain
ident
class
integron
contain
novel
cassett
contain
direct
repeat
bp
portion
gene
strain
repres
four
differ
pfge
type
isol
class
integron
insert
tnpa
gene
type
transposon
tnpa
gene
ident
tnpa
gene
german
isol
ident
ribotyp
contain
class
integron
harbour
mbl
interestingli
class
integron
also
insert
tnpa
gene
transposon
differ
site
conclus
polish
integron
harbour
unusu
gene
cassett
duplic
explain
mechan
involv
delet
segment
ancestr
tandem
repeat
via
slip
strand
replic
mediat
combin
polymeras
integras
interestingli
polish
german
mbl
contain
isol
contain
class
integron
harbour
transposon
case
integron
insert
tnpa
gene
transposon
first
time
mbl
gene
cassett
associ
transposon
observ
add
anoth
level
mobil
gene
cassett
stenotrophomona
maltophilia
strain
greek
hospit
c
masgala
galani
souli
z
chryssouli
h
giamarel
athen
gr
object
stenotrophomona
maltophilia
import
emerg
pathogen
caus
varieti
nosocomi
infect
inher
resist
mani
antibiot
speci
pose
therapeut
challeng
clinician
fluoroquinolon
fq
resist
gramneg
attribut
amino
acid
substitut
quinolon
resistancedetermin
region
qrdr
dna
gyras
gyra
gyrb
topoisomeras
iv
parc
pare
aim
studi
therefor
determin
sequenc
qrdr
gyra
gyrb
parc
gene
nonclon
maltophilia
clinic
isol
resist
quinolon
method
six
nosocomi
isol
five
greek
hospit
collect
period
april
may
studi
suscept
test
perform
agar
diffus
kirbybau
test
etest
accord
nccl
guidelin
epidemiolog
related
isol
assess
pulsefield
gel
electrophoresi
pfge
speirestrict
genom
dna
qrdr
region
gyra
gyrb
parc
strain
amplifi
polymeras
chain
reaction
pcr
use
specif
primer
sequenc
activ
efflux
ciprofloxacin
cip
cefepim
meropenem
chloramphenicol
carbenicillin
aztreonam
tetracyclin
examin
determin
mic
broth
microdilut
method
presenc
absenc
cccp
result
ciprofloxacin
mic
rang
mgl
substitut
posit
gyra
particl
present
six
strain
studi
strain
mic
mgl
harbour
two
aminoacid
chang
posit
gyrb
present
gap
strain
aminoacid
substitut
found
parc
even
singl
strain
cip
mic
mgl
six
isol
show
fourfold
decreas
mic
abovement
antimicrobi
presenc
cccp
suggest
presenc
activ
efflux
system
smeabc
smedef
efflux
pump
overexpress
strain
test
except
one
smedef
pump
overexpress
conclus
clear
correl
appear
mic
ciprofloxacin
mutat
qrdr
gyra
gyrb
parc
activ
efflux
resist
maltophilia
fluoroquinolon
seem
complic
work
requir
clarifi
mechan
behind
wide
phenotyp
variat
observ
object
incid
resist
esbl
antibiot
increas
turkey
studi
invitro
activ
antimicrobi
agent
pseudomona
acinetobact
speci
isol
januari
august
studi
product
esbl
method
identif
suscept
test
done
use
vitec
system
convent
method
bbl
crystal
biomerieux
fr
studi
addit
necessari
minimum
inhibitori
concentr
mic
panresist
strain
determin
agar
dilut
method
result
total
isol
acinetobact
spp
inpati
clinic
outpati
specimen
intens
care
unit
account
posit
cultur
hospitalis
patient
among
acinetobact
speci
acinetobact
spp
saccharolyt
nonhaemolyt
one
acinetobact
spp
asaccharolyt
nonhaemolyt
acinetobact
isol
gener
resist
pseudomona
isol
fiftyseven
per
cent
acinetobact
strain
esblposit
panresist
rate
antimicrobi
test
imipenem
blactam
blactamas
activ
found
activ
suscept
rate
rate
suscept
amikacin
ampicillin
cefazolin
cefotetan
ciprofloxacin
ofloxacin
gentamicin
piperacillin
tobramycin
lower
eightyseven
per
cent
pseudomona
isol
p
aeruginosa
p
fluoresc
onethird
isol
intens
care
unit
fiftysix
per
cent
pseudomona
isol
esblposit
imipenem
piperacillintazobactam
highest
activ
pseudomona
spp
ciprofloxacin
drug
isol
nfold
mic
increas
mic
mgl
n
n
n
n
n
n
cfuml
cfuml
miti
sanguini
erm
never
found
mlsb
strain
erm
b
alway
associ
tet
speci
mstrain
tet
associ
mef
posit
strain
milleri
sanguini
pneumonia
mef
e
posit
southern
blot
analysi
indic
erm
b
tet
alway
hybridis
singl
band
case
suggest
localis
genet
element
contrari
mef
tet
hybridis
differ
fragment
demonstr
differ
localis
streptococc
genom
one
case
mef
e
tet
appear
associ
sequenc
analysi
longpcr
two
strain
erm
strain
recov
food
four
faecal
sampl
healthi
anim
eight
human
five
suscept
test
antimicrobi
agent
perform
agardilut
method
nccl
mutat
gyra
gyrb
parc
gene
analysi
blatem
blaoxa
blashv
gene
determin
pcr
sequenc
tet
aac
ant
apha
sul
aada
cmla
flor
gene
detect
pcr
wherea
dfr
gene
identifi
pcr
rflp
chloramphenicol
acetyltransferas
cat
activ
also
studi
type
integron
analys
pcr
sequenc
result
strain
resist
nalidix
acid
ampicillin
tetracyclin
chloramphenicol
rifampicin
also
trimethoprim
strain
sulphamethoxazol
strain
streptomycin
strain
four
eight
strain
resist
gentamicin
kanamycin
respect
ten
strain
ciprofloxacin
mic
rang
mgl
show
singl
amino
acid
chang
gyra
amino
acid
chang
found
remain
seven
strain
ciprofloxacin
mic
rang
mgl
gyra
parc
chang
four
strain
one
strain
one
strain
one
strain
resist
gene
detect
follow
strain
teta
tetb
seven
cmla
five
aac
iv
three
aac
ii
one
two
six
five
two
six
nine
five
two
new
dfr
gene
also
found
one
strain
none
strain
blaoxa
blashv
ant
flor
gene
five
differ
resist
gene
found
strain
one
strain
harbour
gene
detect
ten
strain
show
one
gene
implic
resist
antimicrobi
agent
cat
activ
found
six
strain
eleven
strain
harbour
one
two
type
integron
includ
follow
gene
cassett
strain
one
six
orf
four
two
type
integron
detect
four
strain
includ
sat
gene
cassett
conclus
multipleantibioticresist
phenotyp
e
coli
strain
differ
origin
associ
heterogen
resist
mechan
locat
integron
acinetobact
baumannii
isol
korea
jk
lee
ys
yoo
ys
lee
ji
yoo
bs
kim
object
acinetobact
baumannii
recogn
import
opportunist
pathogen
nosocomi
infect
resist
fluoroquinolon
among
acinetobact
spp
rapidli
emerg
korea
mechan
resist
fluoroquinolon
associ
mainli
mutat
quinoloneresistancedeterminig
region
qrdr
gyra
gene
dna
gyras
parc
gene
topoisomeras
iv
genet
analysi
fluoroquinolon
resist
baumannii
isol
korea
remain
investig
investig
preval
mutat
dna
gyras
topoisomeras
iv
analys
qrdr
gyra
parc
gene
ciprofloxacinresist
baumannii
isol
korean
hospit
method
total
clinic
isol
baumannii
collect
nontertiari
hospit
baumannii
isol
identifi
api
kit
recarflp
analysi
mic
ciprofloxacin
levofloxacin
determin
accord
criteria
nccl
qrdr
gyra
parc
gene
amplifi
pcr
use
specif
primer
detect
mutat
qrdr
digest
pcr
product
hinf
analys
sequenc
perform
dideoxychain
termin
method
result
ciprofloxacin
levofloxacin
resist
rate
baumannii
isol
respect
ciprofloxacin
levofloxacin
isol
mgl
respect
ciprofloxacinresist
baumannii
substitut
leu
gyra
protein
mutat
gyra
gene
pro
detect
among
baumannii
isol
alter
gyra
mutat
substitut
either
leu
trp
parc
found
one
isol
respect
nine
isol
substitut
ly
two
isol
contain
mutat
parc
conclus
studi
doubl
mutat
codon
gyra
parc
frequent
found
among
baumannii
isol
ciprofloxacin
mic
mgl
parc
protein
novel
substitut
amino
acid
trp
detect
ctxmtype
blactamas
acknowledg
among
import
secondari
extendedspectrum
blactamas
esbl
spread
enterobacteriacea
ctxmproduc
mostli
report
among
nosocomi
isol
recent
also
outpati
anim
point
presenc
larg
reservoir
resist
gene
paper
describ
detect
differ
ctxm
gene
commens
escherichia
coli
healthi
children
live
bolivia
peru
method
e
coli
faecal
swab
healthi
children
four
urban
area
latin
america
two
bolivia
two
peru
suscept
test
detect
esbl
product
carri
recommend
nccl
characteris
blactamas
carri
analyt
isoelectr
focus
ief
molecular
analysi
gene
pcr
sequenc
genet
support
transfer
ctxm
determin
investig
mate
experi
plasmid
profil
southern
blot
experi
phylogenet
group
e
coli
isol
determin
multiplex
pcr
result
larg
screen
subject
carri
investig
antimicrobi
resist
commens
e
coli
healthi
children
peru
bolivia
ceftriaxoneresist
e
coli
isol
recov
four
subject
one
urban
area
four
isol
test
posit
esbl
product
doubledisc
synergi
test
ief
reveal
multipl
band
blactamas
activ
molecular
analysi
show
three
isol
two
bolivia
one
peru
produc
enzym
one
yurimagua
peru
produc
determin
carri
larg
conjug
multidrug
resist
plasmid
heteogen
restrict
profil
differ
isol
also
encod
blactamas
transfer
could
detect
determin
isol
produc
belong
three
differ
phylogenet
group
produc
phylogenet
group
conclus
find
underscor
widespread
distribut
ctxm
gene
role
commens
e
coli
microbiota
play
potenti
reservoir
resist
determin
compar
sensit
isol
success
gener
exhibit
greater
increas
mic
cip
parent
secondstep
mgl
sensit
isol
mic
remain
low
one
secondstep
mutant
mic
mgl
develop
target
site
mutat
gyra
leu
parc
target
site
mutat
found
despit
highlevel
cip
resist
six
ident
aa
substitut
found
gyra
qrdr
parent
mutant
target
site
mutat
found
conclus
mutant
gener
sensit
isol
display
ident
aa
mut
pattern
resist
strain
develop
higher
level
resist
cip
compar
sensit
strain
correl
higher
mutat
frequenc
gyra
mutat
contrast
mutant
sensit
isol
correspond
mutat
seen
method
suscept
measur
use
etest
amoxicillinclavulan
cefoxitin
clindamycin
imipenem
metronidazol
pcr
pcrmap
detect
cfia
gene
element
nucleotid
sequenc
imipenemas
product
assay
appli
result
seven
imipenemresist
b
fragili
strain
detect
produc
imipenemas
cfiaposit
resist
gene
shown
preced
element
alreadi
describ
two
strain
recent
detect
among
isol
usa
nottingham
uk
five
strain
obtain
full
nucleotid
sequenc
element
repres
latter
strain
show
resembl
detect
imipenemresist
b
fragili
strain
japan
may
hybrid
mosaic
form
element
japan
proteom
salmonella
enterica
serovar
typhimurium
characteris
twodimension
hplc
mass
spectrometri
provid
platform
subsequ
proteom
investig
low
level
multipl
antibiot
resist
mar
method
cell
ae
cfu
mean
ae
sd
harvest
liquid
cultur
protein
differenti
fraction
basi
solubl
prepar
repres
cytosol
cell
envelop
outermembran
protein
omp
prepar
digest
treatment
trypsin
peptid
separ
fraction
n
strong
cation
exchang
chromatographi
scx
tryptic
peptid
scx
fraction
separ
revers
phase
chromatographi
detect
iontrap
mass
spectrometri
peptid
assign
protein
consensu
rank
list
compil
use
sequest
result
total
ae
individu
protein
identifi
includ
ae
ae
ae
cytosol
cell
envelop
omp
prepar
respect
signific
correl
observ
r
ae
p
consensu
rank
posit
duplic
cell
prepar
averag
ae
protein
common
duplic
total
outer
membran
protein
detect
omp
prepar
rang
protein
n
previous
associ
mar
e
coli
detect
includ
key
effector
acra
acrb
tolc
ompf
conclus
characteris
salmonella
typhimurium
proteom
provid
inform
discoveri
protein
biomark
multipl
antibiot
resist
enabl
product
specif
test
therebi
evalu
control
strategi
method
sixtytwo
salmonella
strain
isol
patient
affect
td
analys
antimicrobi
suscept
antibiot
ampicillin
amp
amoxicillinclavulan
acid
nalidix
acid
nal
tetracyclin
tet
trimethoprimsulphametoxazol
sxt
chloramphenicol
chl
gentamicin
amikacin
imipenem
norfloxacin
ciprofloxacin
ceftazidim
perform
use
agar
dilut
method
molecular
mechan
resist
sever
antimicrobi
agent
detect
pcr
chloramphenicol
acetyl
transferas
activ
colorimetr
assay
result
twenti
differ
serovar
identifi
salmonella
enteritidi
preval
isol
follow
typhimurium
six
isol
remain
isol
belong
wide
varieti
serovar
highest
level
resist
found
tet
amp
respect
follow
resist
nalidix
acid
resist
nal
relat
presenc
mutat
amino
acid
codon
gyra
gene
isol
resist
ampicillin
differ
blactamas
found
one
isol
temlik
seven
isol
one
case
concomitantli
resist
tet
relat
teta
five
case
tetb
tetg
one
case
resist
chl
relat
presenc
flor
gene
one
case
cat
activ
present
one
strain
differ
dihydrofolatereductas
detect
sxtresist
isol
conclus
wide
varieti
serovar
found
among
salmonella
isol
caus
td
enteritidi
follow
typhimurium
frequent
isol
low
percentag
strain
present
multiresist
howev
highest
level
resist
found
tet
amp
nal
worthi
remark
steadili
increas
resist
nalidix
acid
sinc
surveil
antimicrobi
resist
import
detect
trend
therefor
give
accur
empir
treatment
gene
aac
ib
confer
resist
amikacin
found
four
differ
isol
enterobacteria
endocard
eye
infect
prosthet
devic
lung
infect
infect
organ
identifi
use
biochem
test
gaschromatograph
analysi
pcr
pulsedfield
gel
electrophoresi
use
characteris
size
chromosom
fragment
kb
mutanolysin
mix
lysozym
use
induc
lysi
restrict
enzym
dna
digest
minimum
inhibitori
concentr
four
antimicrobi
agent
clindamycin
erythromycin
linezolid
tetracyclin
p
acn
strain
determin
agardilut
method
accord
nccl
eucast
brucella
basesheep
blood
agar
cfu
inoculum
per
spot
use
agar
plate
incub
anaerob
jar
h
mic
defin
lowest
concentr
antimicrobi
agent
result
mark
chang
appear
growth
compar
control
plate
result
total
cluster
band
pattern
identifi
among
isol
p
acn
similar
major
pfge
type
rang
minimum
inhibitori
concentr
valu
clindamycin
mgl
mgl
rang
mgl
erythromycin
mgl
mgl
rang
mgl
linezolid
mgl
mgl
rang
mgl
tetracyclin
mgl
mgl
rang
mgl
strain
resist
linezolid
strain
tetracyclin
strain
resist
clindamycin
strain
erythromycin
resist
strain
clindamycin
erythromycin
found
croatia
slovenia
suscept
strain
netherland
blood
isol
domin
among
resist
strain
conclus
antibiot
resist
among
p
acn
strain
increas
europ
streptococcu
pneumonia
isol
phenotyp
j
powi
pongport
j
fuller
low
canadian
bacteri
surveil
network
object
erythromycin
resist
increas
among
clinic
isol
streptococcu
pneumonia
spn
canada
examin
longitudin
trend
proport
erm
mef
espress
mlsb
phenotyp
respect
within
canada
distribut
erythromycin
mic
phenotyp
method
spn
isol
collect
canadian
bacteri
surveil
network
compris
privat
hospitalaffili
laboratori
across
canada
laboratori
ask
collect
defin
number
consecut
clinic
isol
follow
steril
site
isol
spn
invitro
suscept
test
perform
broth
microdilut
use
nccl
guidelin
erythromycinresist
isol
classifi
either
mlsb
phenotyp
base
clindamycin
resist
correspond
mef
erm
gene
respect
result
total
isol
includ
patient
age
group
obtain
across
canada
erythromycin
resist
increas
time
emerg
macrolideresist
sp
grow
concern
sinc
macrolid
commonli
use
treat
streptococcu
pneumonia
sp
infect
two
import
mechan
resist
includ
er
ribosom
methylas
erm
gene
macrolid
efflux
mef
gene
mutant
prevent
concentr
mpc
novel
approach
determin
likelihood
antibiot
select
firststep
resist
mutant
larg
popul
cell
determin
mpc
valu
penicillinsensit
pssp
penicillinintermedi
pisp
isol
macrolideazalid
agent
method
minim
inhibitori
concentr
mic
determin
microbroth
dilut
follow
nccl
guidelin
mpc
test
done
plate
cell
onto
agar
plate
contain
drug
incub
co
h
lowest
concentr
prevent
growth
mpc
polymeras
chain
reaction
pcr
perform
select
organ
mpc
mgl
presenc
absenc
macrolideresist
gene
result
object
studi
activ
new
antibiot
daptomycin
clinic
environment
enterococc
isol
differ
antibiot
suscept
method
enterococci
isol
follow
sourc
clinic
isol
patient
locat
three
hospit
hp
central
north
portug
ii
sewag
water
sw
sampl
four
hospit
porto
citi
collect
upstream
sampl
n
leav
downstream
sampl
n
hospit
set
sw
sampl
plate
slanetzbartley
agar
without
antibiot
one
isolatemorpholog
resist
phenotyp
select
antibiot
suscept
determin
use
agar
dilut
method
muellerhinton
media
nccl
recent
increas
infect
caus
resist
gramposit
pathogen
particularli
nosocomi
infect
prompt
search
new
antimicrobi
counter
organ
cyclic
lipopeptid
daptomycin
act
inhibit
cell
wall
synthesi
uniqu
chemic
structur
novel
mode
action
enabl
target
organ
resist
class
agent
current
drug
investig
phase
iii
clinic
trial
treatment
seriou
gramposit
infect
hospitalis
patient
date
investig
efficaci
daptomycin
turkey
aim
studi
evalu
invitro
activ
drug
aureu
enterococcu
strain
isol
infect
turkish
health
centr
materi
method
organ
test
staphylococcu
enterococcu
strain
isol
infect
patient
baskent
univers
hospit
minimum
inhibitori
concentr
mic
determin
etest
isosensitest
agar
medium
result
mic
result
daptomycin
activ
aureu
enterococcu
isol
summaris
tabl
daptomycin
valu
mrsa
mssa
strain
mgl
valu
mrsa
mssa
similar
mgl
respect
daptomycin
mic
valu
vancomycinresist
vancomycinsensit
enterococc
strain
also
similar
tabl
conclus
daptomycin
show
potent
activ
aureu
enterococcu
spp
test
regardless
resist
methicillin
vancomycin
find
invitro
activ
daptomycin
aureu
enterococcu
strain
turkey
first
result
countri
clinic
trial
provid
data
efficaci
daptomycin
case
interact
ertapenem
combin
clarithromycin
cla
levofloxacin
lev
rifampin
rif
vancomycin
van
studi
timekil
method
order
explor
morpholog
chang
induc
ertapenem
cell
expos
mic
microscop
observ
perform
h
incub
result
ertapenem
show
remark
bactericid
activ
pneumonia
test
irrespect
antibiotyp
caus
reduct
initi
inocula
within
h
exposur
strain
result
drug
interact
depict
tabl
synerg
preval
outcom
antagon
never
found
h
exposur
ertapenem
submic
morpholog
alter
observ
mainli
repres
abnorm
elong
cell
follow
antimicrobi
test
penicillin
g
amoxicillin
amoxicillinclavulan
cefaclor
cefuroxim
cefpodoxim
ceftibuten
cefixim
cefotaxim
ertapenem
imipenem
erythromycin
clarithromycin
azithromycin
clindamycin
tetracyclin
chloramphenicol
ciprofloxacin
levofloxacin
moxifloxacin
suscept
antimicrobi
test
use
agar
dilut
method
base
guideli
nccl
result
pneumonia
strain
intermedi
resist
pencillin
highli
suscept
carbapenem
mgl
imipenem
ertapenem
respect
among
penicillinresist
strain
valu
imipenem
ertapenem
mgl
respect
eight
isol
global
seri
would
classifi
resist
imipenem
ertapenem
four
strain
would
consid
resist
therefor
although
imipenem
gener
line
one
dilut
activ
ertapenem
pharmacolog
consider
addit
clinic
data
would
allow
categoris
greater
number
organ
suscept
ertapenem
comparec
imipenem
carbapenem
extraordinarili
activ
whole
group
h
influenza
strain
particularli
ertapenem
inhibit
seri
concentr
mgl
conclus
ertapenem
power
agent
common
respiratori
bacteri
pathogen
includ
gradual
incorpor
effect
resist
mechanim
concentr
mgl
inhibit
except
one
total
organ
consid
ertapenem
least
compar
imipenem
cefotaxim
newer
fluorquinolon
known
effect
microorgan
perform
favour
pharmacokinet
characterist
make
ertapenem
interest
option
treatment
respiratori
tract
infect
object
recent
point
preval
studi
spain
demonstr
high
percentag
resist
aureu
sa
coagulaseneg
staphylococci
con
mani
antimicrobi
agent
follow
oxacillin
sacon
erythromycin
gentamicin
ciprofloxacin
eccmid
glasgow
high
rate
resist
prompt
us
evalu
vitro
activ
new
antimicrobi
agent
isol
method
carri
point
preval
studi
spanish
hospit
collect
staphylococcu
isol
singl
day
total
aureu
oxacillinresist
con
oxacillinresist
studi
identif
antimicrobi
suscept
test
microorgan
perform
laboratori
mic
linezolid
lin
moxifloxacin
mox
quinupristindalfopristin
qd
tigecyclin
tig
determin
microdilut
method
use
muellerhinton
broth
nccl
recommend
aureu
atcc
e
faecali
atcc
use
control
strain
result
mic
valu
mgl
rang
activ
differ
antimicrobi
agent
staphylococcu
spp
summaris
tabl
conclus
isol
test
uniformli
suscept
linezolid
quinupristindalfopristin
tigecyclin
moxifloxacin
less
activ
antimicrobi
test
gener
good
activ
new
antimicrobi
agent
test
show
promis
treatment
infect
due
multiresist
staphylococci
studi
financ
spanish
network
research
infecti
patholog
object
object
studi
evalu
four
commerci
avail
system
ast
challeng
set
streptococcu
pneumonia
spn
known
serotyp
antimicrobi
resist
pattern
method
total
clinic
strain
spn
includ
studi
strain
test
use
two
manual
read
dri
panel
system
sensititr
haemophilu
influenza
pneumonia
trek
diagnost
system
cleveland
oh
microscan
microstrep
plu
dade
behr
mississauga
two
fulli
autom
system
vitek
card
st
laurent
quebec
phoenix
smic
bd
diagnost
spark
md
test
perform
accord
manufactur
guidelin
requir
qualiti
control
test
includ
spn
atcc
includ
common
qualiti
control
strain
system
refer
broth
microdilut
test
mic
perform
nation
centr
streptococcu
edmonton
ab
strain
accord
nccl
recommend
consid
gold
standard
result
differ
serotyp
includ
set
refer
mic
penicillin
penicillini
penicillinr
erythromycinr
seven
strain
ceftriaxon
mening
breakpoint
seven
strain
ofloxacinr
antimicrobi
test
ident
system
penicillin
agreement
within
interpret
categori
system
one
major
error
sensititr
microscan
remaind
minor
error
erythromycin
five
major
error
threephoenix
onemicroscan
onesensititr
remain
minor
error
ceftriaxon
one
major
error
vitek
major
error
microscan
remain
minor
error
quinolon
ofloxacin
mic
vitek
levofloxacin
microscan
sensititr
phoenix
test
result
agent
show
minor
error
system
compar
refer
mic
conclus
system
perform
favour
compar
refer
mic
method
isol
grew
equal
well
dri
panel
autom
system
agent
commonli
use
treat
spn
infect
commerci
system
easi
set
read
provid
equival
result
autom
system
also
provid
expert
interpret
ast
accord
nccl
guidelin
method
total
staphylococc
isol
staphylococcu
aureu
coagulaseneg
staphylococci
isol
clinic
specimen
four
greek
hospit
examin
glycopeptid
suscept
etest
use
two
inoculum
densiti
mc
farland
result
obtain
compar
refer
agar
dilut
method
result
aureu
isol
express
suscept
vancomycin
teicoplanin
accord
nccl
breakpoint
use
inoculum
mc
farland
etest
vancomycin
gave
falseposit
result
specif
respect
contrast
discrep
found
etest
teicoplanin
agar
dilut
method
among
con
isol
express
resist
teicoplanin
remain
suscept
vancomycin
accord
refer
method
etest
teicoplanin
mc
farland
identifi
correctli
isol
sensit
hand
isol
fals
characteris
teicoplaninresist
etest
mc
farland
inoculum
specif
respect
popul
analysi
reveal
falseposit
isol
heteroresist
nt
express
resist
low
frequenc
conclus
studi
indic
use
etest
inoculum
mc
farland
provid
reliabl
sensit
method
detect
teicoplaninresist
staphylococci
without
incur
mani
falseposit
object
streptococci
belong
anginosu
group
main
facult
anaerob
bacteria
involv
oral
maxillofaci
infect
aim
present
studi
investig
antimicrobi
suscept
streptococc
strain
anginosu
group
isol
singl
microbi
agent
associ
bacteria
pu
sampl
collect
dental
abscess
abscess
fascial
space
face
neck
romanian
patient
method
isol
speciat
use
rapid
id
strep
system
biomerieux
franc
antimicrobi
suscept
test
penicillin
g
pg
erythromycin
em
clindamycin
cm
chloramphenicol
cl
tetracyclin
tc
perform
etest
ab
biodisk
sweden
addit
phenotyp
em
resist
identifi
doubl
disc
diffus
test
result
isol
identifi
anginosu
strain
constellatu
five
strain
intermediu
one
strain
mic
mgl
rang
pg
em
cm
cl
tc
isol
suscept
pg
cm
cl
three
strain
anginosu
found
resist
em
show
phenotyp
intermedi
suscept
strain
resist
strain
tc
found
among
isol
three
speci
conclus
pg
still
remain
drug
choic
treatment
infect
caus
bacteria
mix
infect
blactamas
produc
amoxicillinclavulan
acid
augmentin
ampicillinsulbactam
unasyn
indic
use
ii
frequenc
em
resist
low
compar
report
iii
basi
invitro
result
cm
might
altern
blactam
antibiot
patient
allerg
penicillin
mix
infect
penicillinresist
microorgan
object
infect
caus
streptococcu
pneumonia
continu
frequent
worldwid
associ
signific
morbid
mortal
emerg
pneumonia
strain
resist
penicillin
antibiot
complic
treatment
infect
aim
studi
evalu
vitro
suscept
pneumonia
ertapenem
new
carbapenem
comparison
antibiot
method
total
clinic
isol
pneumonia
test
etest
method
mullerhinton
agar
supplement
defibrin
sheep
blood
isol
penicillin
resist
intermedi
mic
lgml
resist
mic
lg
ml
penicillin
sensit
determin
penicillin
pen
vancomycin
van
erythromycin
eri
ciprofloxacin
cip
levofloxacin
lev
ceftriaxon
cef
ertapenem
ert
result
result
penicillin
resist
isol
given
follow
tabl
highest
mic
valu
lgml
found
eri
resist
isol
penicillin
sensit
isol
antimicrobi
resist
found
cip
van
lgml
ert
lgml
respect
conclus
ert
activ
agent
penicillin
resist
sensit
isol
although
isol
sensit
van
ert
mic
ert
alway
lower
isol
find
may
meaning
pharmacodynam
viewpoint
ertapenem
may
import
potent
agent
treatment
invas
pneumococc
infect
recognit
preval
antimicrobi
resist
streptococci
implic
choic
antibiot
therapi
clinic
practic
evalu
antimicrobi
resist
pyogen
sga
isol
among
patient
upper
respiratori
tract
infect
reggio
emilia
itali
data
includ
are
project
antimicrobi
resist
evid
survey
method
studi
conduct
period
includ
patient
symptom
acut
pharyngotonsil
streptococcu
pyogen
isol
identifi
accord
standard
laboratori
techniqu
catalaseneg
bemolit
coloni
isol
sheep
blood
agar
identifi
use
latex
agglutin
test
api
system
sensit
test
done
disc
diffus
accord
nation
committe
clinic
laboratori
standard
nccl
antimicrobi
sensit
penicillin
erytromycin
tetracyclin
clindamycin
rokitamicin
amoxicillinclavulan
determin
result
isol
uniformli
suscept
penicillin
overal
isol
show
resist
erytromycin
also
resist
clindamycin
constitut
resist
erytromycin
resist
trend
area
variabl
preval
rokitamicineresist
isol
reggio
emilia
isol
nation
area
conclus
streptococci
may
virul
organ
caus
septic
nonsept
complic
failur
erad
streptococci
patient
occasion
lead
rheumat
fever
rare
glomerulonephr
emerg
increas
treatment
failur
necessari
consid
altern
therapi
patient
toler
penicillin
date
suggest
import
test
sensit
streptococcu
pyogen
macrolid
particularli
sucha
rokitamicin
lzd
sever
antibiot
efficaci
antibiot
combin
includ
lzd
method
six
strain
nocardia
n
asteroid
two
n
brasiliensi
two
n
farcinica
one
n
spp
one
isol
fineneedl
biopsi
pulmonari
lesion
ht
patient
clinic
sign
symptom
pulmonari
nocardiosi
growth
obtain
convent
bacteri
media
incub
co
h
antimicrobi
suscept
studi
perform
kirbybau
method
mic
determin
microdilut
method
muellerhinton
broth
ii
synerg
studi
perform
disc
techniqu
muellerhinton
ii
agar
use
follow
antibiot
lzd
piperacillintazobactam
tzp
imipenem
imp
trimethoprimsulphametoxazol
tmpsmx
alon
combin
ciprofloxacin
cip
levofloxacin
lvx
ofloxacin
ofx
moxifloxacin
mfx
amikacin
netimicin
net
tobramycin
nn
gentamicin
gm
streptomicin
st
suscept
test
read
h
synerg
studi
plate
observ
h
result
kirbybau
method
strain
suscept
lzd
imp
five
doxycyclin
cefotaxim
ctx
ceftriaxon
cro
cefepim
four
tmpsmx
three
cefamandol
mfx
two
tzp
azithromicin
one
strain
suscept
ampicillin
ampicillinsulbactam
sam
cip
rifampin
two
st
one
antagon
observ
lzd
five
case
tmpsmx
cip
three
conclus
lzd
show
good
vitro
activ
base
preliminari
data
combin
imp
appear
suitabl
initi
treatment
invas
nocardiosi
lzd
may
repres
good
choic
sequenti
oral
therapi
object
telavancin
rapidli
bactericid
agent
multipl
mechan
action
phase
clinic
trial
seriou
gramposit
infect
telavancin
tlv
potent
activ
gramposit
bacteria
exhibit
concentrationdepend
behaviour
studi
effect
ph
media
inoculum
size
vitro
activ
tlv
comparison
vancomycin
van
method
effect
ph
inoculum
size
cfu
ml
mic
determin
enterococcu
faecali
staphylococcu
aureu
streptococcu
pneumonia
accord
nccl
method
effect
inoculum
size
cfuml
media
consist
cationadjust
muellerhinton
broth
mhb
brainheart
infus
broth
bhi
bactericid
activ
determin
tlv
van
aureu
strain
mrsa
timekil
kinet
result
although
increas
inoculum
cfuml
effect
mic
tlv
higher
inocula
cfuml
result
two
eightfold
increas
mic
ph
variat
u
normal
valu
littl
effect
tlv
mic
staphylococci
enterococci
neg
affect
mic
pneumonia
four
dilut
increas
bactericid
activ
tlv
van
unchang
either
mhb
bhi
increas
inoculum
size
increas
time
requir
produc
kill
conclus
high
inoculum
littl
impact
telavancin
inhibitori
bactericid
activ
aureu
unlik
vancomycin
telavancin
abl
decreas
inoculum
cfuml
undetect
level
clinic
achiev
concentr
suggest
possibl
advantag
treat
infect
associ
larg
inocula
organ
recent
shown
patient
chronic
lung
diseas
high
rate
colon
pneumocysti
jiroveci
formerli
known
p
carinii
also
acut
infect
usual
asymptomat
common
first
year
life
howev
far
establish
whether
pathogen
colonis
immunocompet
adult
host
subclin
way
object
evalu
possibl
subclin
infect
p
jiroveci
pc
gener
adult
popul
method
popul
prospect
studi
februaryjuli
includ
first
patient
evalu
unit
work
health
hospit
expos
hospit
environ
previou
year
meet
exclus
criteria
confirm
diagnosi
suspicion
chronic
lung
diseas
neoplasm
immunosuppress
aetiolog
everi
patient
present
clinicalepidemiolog
survey
oropharing
wash
ow
sampl
obtain
gargl
cc
steril
physiolog
serum
analysi
ii
method
presenc
fragment
mtlsurrna
region
pc
analys
ow
mean
nest
polymeras
chain
reaction
pcr
use
primer
result
mean
age
individu
ae
year
old
male
newli
employ
medic
resid
common
servic
staff
nine
administr
staff
pneumocysti
infect
observ
individu
posit
subject
asymptomat
time
enrol
studi
one
taken
steroid
brief
period
time
month
prior
studi
relationship
establish
presenc
pc
infect
age
sex
profession
stand
previou
histori
smoker
tlv
van
reduc
inocula
undetect
level
within
hour
cfuml
case
diagnosi
obtain
mean
nestedpcr
primer
h
genotyp
characteris
perform
sequenc
fragment
locu
mtlsurrna
pc
enabl
identif
four
genotyp
accord
mutat
observ
posit
result
see
tabl
conclus
region
predomin
genotyp
recent
presenc
asymptomat
pneumocysti
jiroveci
carrier
observ
among
patient
suffer
cf
role
natur
histori
diseas
yet
establish
object
determin
occurr
p
jiroveci
colonis
individu
cf
becom
immunocompromis
result
lt
method
prospect
studi
cohort
patient
cf
includ
group
lt
receptor
everi
patient
fill
epidemiolog
survey
sputum
andor
oropharing
lavag
sampl
obtain
diagnosi
p
jiroveci
colonis
reach
mean
nestedpcr
result
total
sputum
sampl
oropharing
lavag
sampl
patient
cf
analys
transplant
patient
receiv
prophylaxi
cotrimoxazol
none
develop
p
pneumonia
followup
period
year
see
tabl
lack
techniqu
obtain
pneumocysti
jiroveci
pc
cultur
made
necessari
develop
molecular
techniqu
detect
resist
differ
drug
punctual
mutat
ala
ser
dhp
gene
associ
failur
treatment
sulpha
drug
worsen
prognosi
pc
pneumonia
nevertheless
import
discoveri
mutat
may
clinic
field
still
establish
aim
studi
ascertain
occurr
strain
dhp
mutat
milieu
clinic
implic
method
includ
studi
patient
diagnos
period
year
hospit
bronchoalveolar
lavag
sampl
andor
sputum
avail
diagnosi
perform
mean
nest
pcr
primer
use
identifi
resist
mutat
mean
restrict
enzym
result
dhp
gene
could
amplifi
nine
identifi
case
see
tabl
conclus
observ
area
elev
occurr
pneumonia
provok
strain
p
jiroveci
mutat
associ
resist
sulpha
drug
support
eurocarinii
project
research
project
consejeria
de
salud
junta
de
andalucia
object
pneumocystosi
remain
difficult
diagnos
current
microbiolog
method
particular
nonhiv
immunodefici
patient
rapid
diagnost
tool
necessari
describ
rapid
reproduc
real
time
pcr
method
detect
quantif
tubulin
p
jiroveci
pj
gene
bronchoalveolar
lavag
bal
sampl
method
quantit
real
time
pcr
develop
detect
quantif
pj
specif
pj
primer
fluorogen
probe
chosen
tubulin
gene
sequenc
plasmid
contain
target
sequenc
use
construct
standard
curv
quantif
dna
extract
perform
qiagen
kit
accord
manufactur
recommend
differ
control
sampl
includ
human
dna
viru
bacteri
fungal
speci
also
test
investig
assay
specif
sampl
control
test
duplic
fiftythre
bal
sampl
sent
laboratori
diagnosi
pneumocystosi
prospect
investig
real
time
pcr
direct
microscop
examin
dme
use
giemsa
stain
direct
immunofluoresc
result
pcr
assay
show
limit
detect
gene
copi
per
millilitr
linear
signal
rang
magnitud
obtain
assay
reproduc
indic
intraassay
cv
valu
obtain
plasmid
standard
pcr
assay
prove
highli
specif
react
tubulin
pj
gene
none
speci
test
pcrneg
sampl
dmeneg
twentyfour
bal
pjposit
pcr
assay
among
eight
posit
dme
rang
pj
dna
gene
copi
per
millilitr
pcrdme
pcrdmesampl
respect
conclus
develop
rapid
sensit
specif
real
time
pcr
diagnosi
quantif
pj
bal
sampl
correl
result
clinic
data
investig
order
establish
clinic
predict
valu
method
basidiomycota
speci
cryptococcu
neoforman
object
analys
suscept
sever
fungal
speci
clinic
relev
belong
divis
basidiomycota
apart
cryptococcu
neoforman
opportunist
fungi
number
infect
due
speci
increas
steepli
past
two
decad
howev
littl
known
suscept
profil
method
collect
clinic
isol
test
strain
recov
period
year
spanish
hospit
clinic
isol
repres
uniqu
isol
patient
suscept
test
follow
strictli
eucastafst
recommend
test
candida
spp
eucast
discuss
document
includ
minor
modif
briefli
micropl
wrap
film
sealer
prevent
medium
evapor
attach
electr
driven
wheel
insid
incub
agit
rpm
incub
c
h
c
parapsilosi
c
krusei
use
qualiti
control
strain
result
tabl
display
rang
geometr
mean
gm
mic
antifung
agent
mgl
classifi
per
basidiomycota
speci
conclus
resist
vitro
amphotericin
b
among
basidiomycota
speci
common
except
asahii
ovoid
ii
cryptococcu
spp
pseudozyma
spp
exhibit
high
mic
flucytosin
fluconazol
iii
r
mucilaginosa
resist
vitro
azol
agent
iv
find
reinforc
need
continu
surveil
program
analys
speci
distribut
antifung
suscept
profil
medic
import
fungal
isol
cryptococcu
neoforman
isol
routin
mycolog
bacteriolog
media
howev
growth
sputum
urin
sampl
particularli
hivinfect
patient
may
confus
andor
obscur
candida
albican
convent
media
due
fact
c
neoforman
c
albican
produc
white
coloni
first
day
isol
brown
coloni
c
neoforman
due
melanin
format
media
contain
phenol
compound
caffeic
acid
contain
staib
guizotia
abyssinica
agar
sa
typic
marker
presumpt
identif
c
neoformansw
assess
anoth
medium
pal
agar
pa
contain
caffeic
acid
heliantu
annu
detect
phenoloxidas
activ
c
neoforman
strain
differ
c
neoforman
coloni
c
albican
method
total
c
neoforman
strain
use
human
isol
hiv
eight
environment
isol
c
neoforman
eight
c
albican
reffer
strain
use
control
detect
phenoloxidas
activ
strain
streak
pa
sa
plate
incub
c
day
coloni
colour
examin
visual
everi
h
day
order
investig
differenti
abil
pa
c
neoforman
c
albican
primari
cultur
medium
randomli
select
c
neoforman
strain
use
togeth
refer
c
albican
strain
dual
combin
sa
sda
use
along
pa
test
plate
inocul
streak
preadjust
inoculum
mix
suspens
incub
c
day
coloni
colour
count
read
visual
everi
h
day
result
yeast
isol
test
grew
well
pa
c
neoforman
isol
grew
typic
brown
color
coloni
select
detect
pa
sa
plate
h
incub
indistinguish
white
coloni
growth
mix
suspens
sda
coloni
count
signific
mean
differenti
suggest
pa
sa
select
stimul
c
neoforman
growth
differ
coloni
colour
conclus
pa
excel
primari
differenti
medium
evidenti
c
neoforman
isol
easi
inexpens
prepar
readili
avail
seed
routin
use
microbiolog
laboratori
could
use
easi
rapid
diagnosi
c
neoforman
infect
wide
rang
patient
popul
includ
particularli
hiv
individu
hivat
risk
patient
result
year
nonhivinfect
patient
cryptococcosi
identifi
patient
avail
medic
record
studi
mean
age
year
rang
year
femal
twenti
patient
least
one
associ
underli
medic
condit
three
common
underli
condit
includ
system
lupu
erythematosu
diabet
mellitu
malign
c
neoforman
recov
cerebrospin
fluid
csf
sputumbronchoalveolar
lavag
fluid
blood
site
cryptococc
infect
gastrointestin
tract
bone
joint
lymph
node
skin
soft
tissu
eight
patient
dissemin
cryptococcosi
present
mening
abnorm
chest
radiographi
serum
cryptococc
antigen
test
patient
yield
posit
titr
rang
patient
csf
cryptococc
antigen
test
patient
yield
posit
titr
rang
patient
patient
treat
amphotericin
b
subsequ
fluconazol
two
patient
initi
misdiagnos
treat
tuberculosi
two
patient
lost
followup
overal
mortal
rate
conclus
cryptococcosi
uncommon
nonhivinfect
patient
cryptococcosi
recognis
possibl
caus
mening
pulmonari
infect
especi
patient
underli
immunocompromis
condit
cryptococc
antigen
may
help
cultur
need
diagnosi
earli
recognit
cryptococcosi
appropri
antifung
therapi
patient
may
improv
clinic
outcom
method
mice
infect
inoculum
size
cfu
per
mous
treatment
start
h
postinfect
continu
day
mice
treat
drug
alon
combin
amphotericin
b
given
intraperiton
ip
mgkgday
flucytosin
given
per
os
po
mgkgd
four
possibl
combin
test
control
group
receiv
either
water
po
glucos
ip
includ
group
contain
five
mice
day
mice
sacrif
quantit
cultur
brain
lung
spleen
done
result
flucytosinesuscept
isol
decreas
approxim
log
cfug
observ
three
organ
flucytosin
monotherapi
lung
spleen
amphotericin
b
monotherapi
combin
flucytosin
mgkgday
amphotericin
b
mgkgday
significantli
decreas
fungal
burden
three
organ
compar
drug
alon
highest
efficaci
lung
antifung
interact
consid
synergist
flucytosineresist
isol
flucytosin
alon
concentr
ineffect
three
organ
amphotericin
b
alon
ineffect
brain
poorli
activ
spleen
decreas
approxim
log
cfug
activ
lung
decreas
approxim
log
cfug
combin
flucytosin
mgkgday
amphotericin
b
mgkg
day
consid
synergist
signific
decreas
fungal
burden
brain
spleen
lung
conclus
synergist
interact
observ
vivo
amphotericin
b
flucytosin
even
brain
flucytosinesuscept
resist
isol
determin
vitro
addit
flucytosin
amphotericin
b
modifi
activ
amphotericin
b
flucytosineresist
clinic
isol
cryptococcu
neoforman
three
differ
techniqu
method
ten
flucytosineresist
mic
lgml
clinic
isol
c
neoforman
use
checkerboard
studi
perform
accord
nccl
document
modifi
assess
antifung
interact
micropl
read
spectrophotometr
h
incub
interact
interpret
fic
indic
timekil
studi
done
rpmi
ph
start
inoculum
cfuml
flucytosin
alon
combin
test
concentr
lg
ml
amphotericin
b
lgml
interact
evalu
h
incub
suscept
test
rpmiagar
ph
mic
antifung
determin
h
incub
result
mic
drug
alon
determin
nccl
methodolog
rang
lgml
geometr
mean
mic
lgml
flucytosin
rang
lgml
amphotericin
b
checkerboard
studi
synergi
observ
addit
test
isol
antagon
observ
antifung
interact
observ
timekil
studi
synergist
four
isol
addit
one
indiffer
four
isol
possibl
detect
synergi
strain
chosen
technic
condit
object
yeast
ident
unknown
biochem
profil
id
c
bio
franc
isol
five
hospitalis
patient
univers
hospit
blood
cultur
n
tracheal
secret
n
method
isol
identifi
sequenc
itsregion
phenotyp
sdspage
pattern
suscept
antimycot
agent
investig
genotyp
pfgeand
rapdanalysi
perform
result
sequenc
analysi
region
five
patient
isol
reveal
homolog
cactophil
speci
sporopachydermia
cereana
identif
confirm
cb
netherland
sdspage
patient
isol
two
refer
strain
cb
show
ident
protein
pattern
two
refer
strain
differ
pfge
pattern
three
five
band
respect
rang
mb
patient
isol
show
nearli
ident
pattern
six
band
analysi
isol
rapdpcr
primer
previous
use
type
aspergilli
reveal
ident
patient
isol
wherea
refer
strain
differ
seven
isol
suscept
amphotericin
b
fluconazol
itraconazol
voriconazol
determin
microdilut
assay
etest
conclus
first
descript
sporopachydermia
cereana
human
sourc
strain
remain
unknown
sinc
epidemiolog
link
found
patient
continu
ambulatori
periton
dialysi
analysi
experi
singl
centr
cpk
subudhi
ledson
ks
raman
waldek
pr
chadwick
salford
uk
object
fungal
periton
seriou
complic
patient
continu
ambulatori
periton
dialysi
capd
associ
high
rate
morbid
mortal
retrospect
review
episod
fungal
periton
hospit
period
attempt
identifi
risk
factor
determin
clinic
outcom
patient
method
patient
capd
fungal
periton
identifi
computeris
mycolog
laboratori
databas
audit
templat
design
use
collect
relev
inform
patient
medic
record
result
episod
fungal
periton
patient
period
episod
fungal
periton
patient
whose
medic
note
could
review
c
albican
c
parapsilosi
two
predomin
speci
isol
periton
effluent
studi
patient
receiv
antibiot
month
prior
episod
fungal
periton
patient
intraperiton
antibiot
manag
bacteri
periton
attribut
mortal
fungal
periton
despit
therapi
includ
earli
remov
periton
dialysi
cathet
prolong
antifung
therapi
periton
dialysi
cathet
remov
patient
conclus
fungal
periton
rel
uncommon
complic
patient
capd
associ
signific
morbid
mortal
prior
antibiot
use
recent
bacteri
periton
found
risk
factor
develop
fungal
periton
treatment
requir
administr
antifung
agent
earli
remov
periton
cathet
prompt
diagnosi
fungal
periton
earli
institut
therapi
essenti
better
outcom
manag
fungal
periton
patient
capd
incid
lifethreaten
fungal
infect
rise
proport
increas
number
subject
risk
includ
aid
transplant
cancer
elderli
patient
prematur
infant
present
identif
frequent
encount
fungal
pathogen
base
array
differ
laboratori
method
often
requir
sever
day
simpl
rapid
diagnosi
fungal
infect
warrant
time
effici
therapi
remain
goal
sought
studi
use
intern
transcrib
spacer
region
within
ribosom
dna
gene
complex
molecular
target
gener
assay
identif
pathogen
fungi
method
dna
cultur
yeast
filament
fungi
extract
releas
subsequ
amplif
polymorph
spacer
use
oligonucleotid
prime
region
ribosom
gene
univers
conserv
throughout
fungal
kingdom
short
amplicon
fragment
sequenc
use
pyrosequenc
analysi
speci
determin
direct
local
blast
fungal
databas
perform
result
isol
laboratori
strain
compris
clinic
signific
opportunist
yeast
mould
pathogen
analys
long
sequenc
signatur
show
provid
enough
discriminatori
power
unambigu
identif
speci
includ
studi
highli
signific
evalu
obtain
blast
search
local
public
genbank
databas
contrast
convent
fungal
identif
method
speci
identif
time
organ
nearli
h
object
dissemin
trichosporonosi
emerg
diseas
immunocompromis
patient
particularli
persist
granulocytopenia
studi
carri
identifi
local
clinic
isol
trichosporon
speci
biochem
molecular
method
molecular
type
also
perform
intraspeci
divers
method
twentynin
isol
trichosporon
speci
recov
clinic
specimen
kuwait
first
speciat
vitek
yeast
identif
system
pcr
amplif
assay
base
sequenc
within
intern
transcrib
spacer
rdna
develop
specif
detect
three
trichosporon
spp
viz
asahii
mucoid
jirovecii
methodolog
establish
refer
strain
appli
speciesspecif
amplif
genom
dna
clinic
isol
result
confirm
extend
direct
dna
sequenc
rdna
type
isol
intraspeci
divers
perform
randomli
amplifi
polymorph
dna
rapd
analysi
use
two
differ
primer
result
vitek
yeast
identif
system
identifi
clinic
isol
kuwait
asahii
howev
use
asahiispecif
primer
genom
dna
isol
amplifi
amplif
obtain
remain
four
isol
ident
asahii
isol
confirm
direct
dna
sequenc
region
rdna
three
randomli
select
isol
ident
remain
four
nont
asahii
isol
asteroid
establish
amplif
rdna
panfung
primer
follow
sequenc
rapd
pattern
asahii
isol
exhibit
littl
intraspeci
divers
howev
type
pattern
four
asteroid
isol
differ
pattern
obtain
asahii
isol
trichoderma
infect
report
patient
undergo
periton
dialysi
immunocompromis
transplant
recipi
rapid
accur
identif
opportunist
fungi
crucial
choic
adequ
therapeut
intervent
studi
taxonom
posit
clinic
trichoderma
strain
includ
human
pathogen
two
nasal
mucu
isol
method
examin
clinic
isol
origin
identifi
base
morpholog
identif
trichoderma
strain
difficult
morpholog
charact
consid
use
molecular
techniqu
confirm
ident
examin
clinic
trichoderma
isol
studi
phylogenet
posit
within
genu
sequenc
analysi
intern
transcrib
spacer
region
carri
primer
random
amplifi
polymorph
dna
analysi
carri
use
opa
random
primer
kit
qiagen
isoenzym
analysi
peptidas
b
phosphoglucomutas
enzym
perform
cellulos
acet
electrophoresi
report
candida
speci
inhibit
growth
aspergillu
fumigatu
cocultur
peptonglucos
agar
pga
especi
seal
agar
plate
c
glabrata
c
albican
prove
major
inhibitor
studi
author
specul
colonis
candida
speci
may
delay
definit
diagnosi
aspergillosi
sputum
clinic
specimen
assess
possibl
impact
find
clinic
diagnost
fumigatu
question
role
use
media
method
experi
randhawa
et
al
repeat
sabouraud
dextros
agar
sda
candidaii
agar
cii
columbia
agar
ca
cled
agar
seal
unseal
agar
plate
cocultiv
fumigatu
c
albican
six
strain
c
glabrata
one
strain
c
krusei
three
strain
c
tropicali
three
strain
result
sda
growth
fumigatu
strongli
inhibit
candida
speci
especi
seal
plate
unseal
plate
c
glabrata
c
albican
strong
inhibitor
well
wherea
c
tropicali
c
krusei
weak
inhibitor
cocultiv
strong
inhibitor
h
visibl
growth
fumigatu
obtain
result
concord
report
pga
differ
growth
inhibit
sda
cii
contrast
ca
test
candida
speci
weak
inhibitor
seal
plate
unseal
plate
relev
inhibit
regist
c
tropicali
c
albican
wherea
c
glabrata
c
krusei
weak
inhibitor
h
cocultiv
visibl
growth
fumigatu
obtain
regardless
test
candida
strain
growth
inhibit
cled
compar
ca
conclus
avoid
contamin
seal
agar
plate
often
use
isol
fumigatu
clinic
laboratori
specimen
might
heavili
contamin
candida
speci
cultur
sda
delay
growth
growth
inhibit
aspergillu
might
concern
result
suggest
problem
might
overcom
simultan
inocul
glucosepoor
medium
eg
ca
plate
prolong
incub
plate
h
invas
candidiasi
increas
dramat
past
decad
contribut
nonalbican
candida
spp
includ
c
tropicali
invas
infect
rise
yet
littl
known
molecular
epidemiolog
therefor
effect
type
system
requir
trace
epidemiolog
distribut
pattern
addit
restrict
endonucleas
analysi
genom
dna
reag
follow
pulsedfield
gel
electrophoresi
pfge
differ
amplificationbas
method
studi
arbitrarili
prime
ap
pcr
lowstring
condit
set
differ
arbitrari
oligonucleotid
g
c
content
interrepeat
ir
pcr
base
microand
minisatellit
sequenc
eucaryot
telomer
motif
use
eight
differ
primer
result
compar
obtain
phenotyp
isol
fouriertransform
infrar
spectroscopi
ftir
fingerprint
c
tropicali
refer
strain
clinic
isol
differ
european
asian
center
includ
studi
rank
order
discriminatori
abil
among
genotyp
method
follow
reag
use
bssh
ii
appcr
irpcr
contrast
restrict
enzym
use
bssh
ii
reveal
seri
distinct
band
region
bp
approxim
kb
regard
appcr
fingerprint
random
primer
g
c
content
show
best
discriminatori
power
prolong
ramp
time
min
appli
contrast
irpcr
shown
suitabl
genotyp
c
tropicali
isol
use
ward
algorithm
first
deriv
spectra
ftir
show
main
branch
two
group
divid
sever
subgroup
depend
heterogen
level
select
gener
ftir
less
discriminatori
reag
easier
perform
classif
deriv
reag
ftir
complet
congruent
strain
repres
major
profil
epidemiolog
unrel
appear
widespread
sever
centr
includ
find
indic
reag
follow
pfge
use
molecular
method
investig
interstrain
variat
within
speci
c
tropicali
depend
upon
primer
design
appcr
may
offer
fairli
well
altern
molecular
fingerprint
method
addit
wholeorgan
fingerprint
ftir
provid
tool
suffici
resolv
power
distinguish
isol
candida
speci
object
variou
member
class
zygomycet
known
agent
opportunist
infect
men
anim
thermophil
organ
rhizomucor
miehei
practic
theoret
signific
member
fungal
group
aim
present
studi
clone
characteris
coenzym
reductas
hmgcoa
reductas
gene
hmg
r
miehei
elabor
direct
select
method
transform
base
lovastatin
resist
requir
usag
auxotroph
marker
method
genom
dna
librari
genom
dna
use
templat
pcr
reaction
deriv
wildtyp
r
miehei
atcc
genom
librari
screen
subclon
extract
dna
sequenc
construct
plasmid
perform
use
standard
techniqu
peg
mediat
protoplast
transform
use
introduc
express
vector
r
miehei
lgml
lovastatin
use
select
agent
transform
analys
pcr
southern
hybridis
result
genom
librari
construct
chromosom
dna
r
miehei
screen
use
probe
amplifi
pcr
degener
primer
design
conserv
region
hmg
result
analysi
genom
insert
bp
contain
entir
hmg
gene
clone
pbluescript
vector
use
sequenc
result
complet
nucleotid
sequenc
determin
analys
put
protein
sequenc
prove
aa
length
r
miehei
transform
plasmid
contain
hmg
gene
transform
could
select
lovastatin
resit
analysi
transform
optimis
transform
also
done
object
expand
set
data
demonstr
opportunist
pathogen
role
rhizomucor
speci
genu
involv
two
speci
r
pusillu
r
miehei
thermophhil
natur
characterist
morpholog
featur
clearli
distinct
member
mucoral
identif
rhizomucor
isol
speci
level
seem
problemat
frequent
result
misidentif
speci
name
remain
determin
purpos
present
studi
broaden
basi
knowledg
afford
method
simpl
quick
unambigu
identif
two
rhizomucor
speci
method
carbon
sourc
utilis
analysi
rhizomucor
isol
use
differ
compound
isoenzym
analysi
isol
test
five
enzym
system
random
amplifi
polymorph
dna
rapd
analysi
isol
bp
oligonucleotid
primer
lovastatin
inhibit
test
isol
result
four
carbon
compound
identifi
whose
utilis
show
clear
differ
r
miehei
r
pusillu
isol
sucros
glycin
phenylalanin
alanin
stain
pattern
three
enzym
system
also
show
two
differ
electromorph
correl
perfectli
two
investig
rhizomucor
speci
rapd
analysi
reveal
higher
genet
variabl
howev
genet
variabl
found
differ
r
pusillu
r
miehei
latter
reveal
lessintraspecif
polymorph
result
highli
differ
amplif
pattern
two
rhizomucor
speci
rapd
band
characterist
r
miehei
r
pusillu
isol
could
identifi
suscept
r
miehei
r
pusillu
lovastatin
differ
cultur
condit
investig
also
r
pusillu
prove
significantli
sensit
lovastatin
r
miehei
malt
extract
agar
ph
supplement
lgml
lovastatin
inhibit
growth
r
pusillu
allow
vigor
growth
r
miehei
conclus
besid
determin
easili
countabl
charact
identif
rhizomucor
isol
experiment
data
provid
inform
concern
genet
variabl
speci
extent
genet
polymorph
differ
two
rhizomucor
speci
substanti
polymorph
found
among
r
pusillu
strain
investig
r
miehei
strain
prove
almost
homogen
elabor
simpl
reliabl
method
speci
level
differenti
result
mic
ambpvp
complex
time
lower
compar
amb
show
lowest
mic
mfc
candida
spp
slighti
lower
equal
aspergillu
spp
kill
activ
h
exposur
c
albican
amb
ambpvp
complex
mic
reach
log
complex
compar
log
amb
uptak
macrophag
h
three
time
lower
complex
amb
haemolyt
activ
ldh
releas
approxim
three
time
lower
complex
amb
conclus
ambpvp
complex
show
improv
antifung
activ
compar
amb
candida
spp
aspergillu
spp
accumul
lower
level
amb
eucaryot
cell
may
explain
lower
toxic
data
demonstr
potenti
benefit
new
formul
suggest
futur
applic
introduct
voriconazol
altern
amphotericin
b
treatment
invas
aspergillosi
voriconazol
high
oral
bioavail
therefor
promis
outpati
treatment
well
toler
one
noncompar
studi
report
mild
cutan
sideeffect
patient
case
man
year
chronic
granulomat
diseas
diagnos
probabl
invas
pulmonari
aspergillosi
accord
eortcmsg
definit
outpati
treatment
oral
voriconazol
mg
bid
start
patient
improv
week
develop
profound
erythema
sunexpos
area
face
hand
voriconazol
stop
erythema
resolv
within
week
six
week
later
patient
relaps
voriconazol
reinstitut
despit
protect
measur
redevelop
profound
skin
erythema
friabil
sunexpos
area
week
week
lesion
evolv
desquam
small
ulcer
hand
week
patient
larg
area
bulla
desquam
superfici
ulcer
lip
face
hand
voriconazol
switch
itraconazol
oral
solut
lesion
heal
within
week
case
man
year
diabet
mellitu
underw
aortobifemor
vascular
graft
reoper
thrombot
problem
multipl
cultur
explant
graft
yield
aspergillu
fumigatu
vascular
graft
infect
complic
acroilei
arthriti
right
knee
ankl
amphotericin
b
given
month
thereaft
patient
discharg
oral
voriconazol
mg
bid
month
asymptomat
hyperpigment
sunexpos
area
notic
week
small
vesicl
appear
sun
expos
area
face
neck
arm
leg
vesicl
evolv
bulla
diamet
cm
ruptur
day
crusta
form
lesion
heal
week
new
lesion
continu
appear
old
lesion
heal
voriconazol
switch
itraconazol
oral
solut
lesion
resolv
within
week
discuss
skin
reaction
mainli
rash
pruritu
phototox
induc
erythema
known
mostli
mild
sideeffect
voriconazol
sever
facial
erythema
cheiliti
report
five
patient
report
sever
lateonset
phototox
skin
reaction
two
patient
postmarket
surveil
incid
impact
lateonset
cutan
sideeffect
warrant
object
describ
safeti
efficaci
voriconazol
patient
treat
within
compassionateus
programm
method
retrospect
studi
patient
pt
receiv
voriconazol
compassionateus
programm
spain
treatment
invas
fungal
infect
refractori
intoler
approv
antifung
therapi
depend
toler
voriconazol
administ
either
intraven
oral
iv
voriconazol
administ
load
dose
mgkg
h
day
follow
h
thereaft
oral
voriconazol
administ
load
dose
h
day
follow
mg
twice
day
per
patient
weigh
kg
respect
feasibl
rout
administr
voriconazol
chang
iv
oral
outcom
assess
investig
end
therapi
last
visit
success
complet
partial
respons
stabl
infect
failur
base
protocoldefin
criteria
result
period
april
novemb
patient
femal
review
age
patient
rang
year
common
underli
diseas
leukaemia
nineteen
patient
present
neutropenia
common
fungu
isol
aspergillu
spp
follow
candida
spp
total
fungal
isol
recov
tissu
follow
blood
bronchoalveolar
lavag
prior
voriconazol
patient
receiv
amphotericin
b
itraconazol
fluconazol
four
caspofungin
reason
use
voriconazol
failur
antifung
drug
intoler
failur
intoler
advert
event
report
gener
mild
moder
sever
transient
natur
revers
twentynin
patient
respond
voriconazol
therapi
four
case
infect
progress
conclus
voriconazol
provid
high
rate
cure
good
overal
toler
data
confirm
efficaci
voriconazol
treatment
invas
fungal
infect
special
invas
aspergillosi
even
patient
intoler
refractori
convent
antifung
therapi
introduct
need
safe
effect
antifung
anid
novel
echinocandin
antifung
agent
demonstr
efficaci
mucos
invas
infect
due
candida
spp
current
regulatori
review
hepat
toxic
common
reason
failur
new
drug
rule
propos
detect
evalu
hepat
safeti
new
agent
via
monitor
hepatobiliari
paramet
potenti
signal
toxic
object
evalu
hepat
safeti
anid
method
patient
pt
confirm
oesophag
candidiasi
enrol
multin
randomis
control
doubl
blind
doubledummi
phase
clinic
trial
obtain
inform
consent
pt
randomis
receiv
iv
anid
mg
oral
fluconazol
flu
mg
plu
correspond
placebo
pt
return
daili
day
therapi
followup
fu
week
endoftherapi
eot
hepatobiliari
paramet
alt
ast
alp
bili
obtain
baselin
day
eot
eot
day
fu
threshold
clinic
signific
cs
increas
baselin
prospect
specifi
prior
unblind
variou
signific
combin
chang
alt
upper
limit
normal
uln
plu
bili
uln
result
total
pt
aid
enrol
took
one
nonantifung
medic
concomitantli
number
percentag
pt
cs
increas
shown
tabl
alt
similar
result
obtain
hepat
valu
note
also
differ
arm
variou
prospect
defin
combin
valu
consid
conclus
immunocompromis
popul
pt
multipl
medic
signal
hepat
effect
anidulafungin
appar
object
scedosporium
prolifican
caus
therapyrefractori
invas
infect
high
mortal
immunocompromis
patient
test
combin
effect
posaconazol
po
investig
antifung
triazol
granulocytemacrophag
colonystimul
factor
gmcsf
ex
vivo
activ
neutrophil
pmn
prolifican
method
balbc
mice
treat
ng
murin
gmcsf
salin
sc
daili
day
pmn
isol
gmcsfor
salinetr
mice
incub
po
hypha
effector
cell
target
ratio
per
cent
damag
prolifican
hypha
assess
xtt
metabol
assay
anova
anova
tukey
test
use
multipl
comparison
proteinfre
unbound
fraction
antibiot
concentr
use
pkpd
calcul
reliabl
easi
measur
protein
bind
therefor
need
three
method
usual
recommend
ultrafitr
f
dialysi
ultracentrifug
c
seen
method
compar
simultan
antibiot
studi
three
method
estim
serum
protein
bind
erythromycin
method
portion
pool
human
serum
use
experi
three
concentr
erythromycin
mgl
respect
subject
three
protein
bind
method
erythromycin
concentr
serum
filtratedialysatesupernat
measur
bioassay
serum
pb
standard
protein
bind
calcul
formula
erythromycin
concentr
serumfiltr
dialys
supernat
serum
per
cent
correct
bind
serumfre
control
f
amicon
ufvial
filter
ad
one
ml
serum
centrifug
fixedangl
rotor
sorval
centrifug
g
min
result
approx
ml
ultrafiltr
dialysi
tube
spectrapor
mwco
piec
cm
tie
end
ad
ml
serum
tube
place
uform
plastic
tube
centrifug
free
angl
rotor
centrifug
g
min
excess
water
remov
tube
centrifug
g
min
result
approxim
ml
dialys
c
beckman
ultracentrifug
type
type
ti
rotor
use
beckman
ultraclear
centrifug
tube
fill
ml
serum
sampl
centrifug
g
h
c
ml
supernat
remov
pipett
result
three
sampl
mgl
erythromycin
follow
serum
protein
bind
found
f
c
respect
conclus
within
variat
method
found
slight
concentr
relat
bind
littl
differ
method
result
compar
publish
data
method
singl
mg
dose
administ
oral
follow
blood
periton
fluid
sampl
hour
afterward
concentr
moxifloxacin
estim
microbiolog
assay
vital
sign
observ
laboratori
test
ecg
perform
everi
h
result
mean
ae
sd
moxifloxacin
serum
conclus
oral
intak
moxifloxacin
anur
patient
capd
accompani
adequ
penetr
periton
caviti
h
intak
promis
agent
therapi
spontan
periton
object
evalu
pharmacokinet
levofloxacin
anur
patient
undergo
chronic
haemofiltr
establish
oral
regimen
deliv
therapeut
trough
serum
level
method
first
phase
studi
anur
patient
given
singl
oral
dose
mg
levofloxacin
patient
underw
haemofiltr
h
second
phase
day
patient
receiv
mg
daili
day
consecut
phase
haemofiltr
perform
day
phase
blood
sampl
regular
time
interv
concentr
levofloxacin
estim
microbiolog
assay
result
first
phase
estim
mean
aes
concentr
ae
ae
ae
ae
ae
ae
ae
mgl
h
intak
respect
phase
estim
mean
aes
respect
concentr
arteri
venou
end
fistula
ae
ae
mgl
p
first
hour
haemofiltr
ae
ae
mgl
p
ns
second
hour
haemofiltr
ae
ae
mgl
p
fourth
hour
haemofiltr
second
phase
estim
mean
aes
concentr
day
haemofiltr
day
day
haemofiltr
day
haemofiltr
day
day
haemofiltr
day
haemofiltr
ae
ae
ae
ae
ae
ae
ae
mgl
respect
conclus
levofloxacin
rapidli
elimin
haemofiltr
oral
administr
propos
regimen
mg
daili
day
result
adequ
therapeut
though
serum
level
day
allow
applic
case
infect
gramposit
cocci
method
total
patient
includ
patient
receiv
mg
linezolid
intraven
everi
h
cvvh
perform
use
highli
permeabl
polysulphon
membran
pshf
baxter
germani
av
freseniu
germani
mean
blood
flow
rate
ultrafiltr
rate
ae
mlmin
ae
mlmin
respect
postdilut
perform
linezolid
concentr
serum
ultrafiltr
determin
highperform
liquid
chromatographi
hplc
result
mean
linezolid
serum
concentr
peak
cmax
ae
lgml
mean
trough
level
cmin
ae
lgml
elimin
halflif
ae
h
total
clearanc
cltot
haemofiltr
clearanc
clhf
volum
distribut
vd
ae
l
h
ae
mlmin
ae
l
respect
conclus
result
show
patient
sever
gramposit
infect
undergo
cvvh
treat
effect
dosi
mg
linezolid
everi
h
object
antibiot
known
bind
plasma
protein
mainli
albumin
lead
chang
pk
antibiot
thu
chang
pharmacolog
suppos
protein
bind
pb
taken
consider
exce
free
fraction
antibiot
activ
examin
hypothes
perform
kill
kinet
h
influenza
four
blactam
antibiot
divers
pb
meropenem
pb
cefotaxim
cf
pb
cefoxitin
cx
pb
faropenem
f
pb
cf
cx
simul
free
fraction
slightli
reduc
effect
antibiot
lower
concentr
f
addit
albumin
lead
reduc
effect
therefor
higher
valu
howev
reduct
pronounc
experi
free
concentr
simul
tabl
concentr
mic
emax
obtain
protein
bind
effect
activ
f
data
deriv
vitro
model
show
cf
cx
addit
albumin
caus
reduct
antibacteri
activ
ad
albumin
f
mark
reduct
effect
observ
moreov
simul
free
fraction
cx
f
lead
reduc
effect
conclus
pb
influenc
activ
antibiot
narrow
concentr
rang
effect
maxim
effect
drug
bound
influenc
could
observ
howev
hypothesi
free
fraction
activ
could
confirm
pk
pd
indic
good
predictor
highli
protein
bound
drug
c
fuhst
barger
b
wiedemann
bonn
object
mani
author
use
pkpd
indic
predict
efficaci
antibiot
accord
intern
societi
antiinfect
pharmacolog
isap
indic
refer
nonprotein
bound
fraction
drug
free
fraction
activ
hypothesi
examin
possibl
free
fraction
activ
therefor
perform
kill
kinet
three
differ
strain
faropenem
highli
protein
bound
antibiot
protein
bind
method
kill
kinet
aureu
mic
mgl
h
influenza
mic
mgl
pneumonia
mgl
perform
pharmacolog
vitro
model
faropenem
f
three
dose
scheme
simul
mg
dose
without
human
serum
albumin
cmax
mgl
mg
hl
ii
mg
dose
gl
albumin
free
cmax
mgl
free
mg
hl
iii
dose
scheme
resembl
free
fraction
mg
cmax
mgl
mg
hl
pkpd
indic
cmaxmic
aucmic
mic
pd
paramet
aac
area
curv
indic
effect
f
calcul
result
tabl
show
calcul
pkpd
indic
base
free
fraction
aac
valu
free
fraction
would
activ
differ
aac
valu
simul
ii
iii
howev
pneumonia
aureu
effect
ii
similar
wherea
effect
iii
much
lower
h
influenza
whose
mic
rang
free
cmax
differ
effect
ii
effect
iii
lower
differ
reflect
pk
pd
indic
ii
iii
conclus
free
fraction
f
activ
addit
albumin
lead
higher
effect
calcul
indic
auc
mic
cmaxmic
mic
base
free
fraction
reflect
actual
condit
object
previou
data
shown
use
pneumonia
sp
strain
rais
coa
mic
bacteri
inoculum
strain
mic
may
impact
significantli
antibacteri
effect
measur
abe
howev
none
data
analys
collect
aim
studi
perform
anova
anova
combin
dataset
establish
factor
signific
determin
abe
sp
strain
rais
coa
mic
method
vitro
pharmacokinet
model
use
simul
pharmacokinet
enhanc
pe
mg
amoxicillin
amox
mg
clavulan
standard
formul
sf
mg
clav
coamoxiclav
coa
six
sp
strain
rais
coa
mic
mgl
mic
pe
coa
sf
simul
perform
triplic
use
brain
heart
infus
broth
h
initi
bacteri
inoculum
either
cfuml
anova
anova
use
exploit
factori
structur
data
analys
effect
mic
drug
formul
initi
bacteri
inoculum
abe
measur
area
bacteri
kill
curv
aubkc
result
three
factor
inoculum
mic
formul
affect
abe
measur
ln
signific
interact
note
formul
inoculum
formul
mic
suggest
formul
mic
differ
effect
ln
inocula
ln
increas
increas
mic
howev
mean
ln
increas
standard
formul
greater
pe
coa
interact
inoculum
mic
conclus
pe
coa
like
mic
resist
sp
sf
especi
strain
coa
mic
mgl
data
confirm
mic
impact
upon
coa
abe
drug
formul
greatest
mic
effect
object
cystic
fibrosi
cf
multisystem
diseas
due
defect
gene
chromosom
codifi
alter
cystic
fibrosi
transmembran
regul
protein
median
surviv
improv
thank
aggress
treatment
includ
higher
dose
antibiot
infus
day
cf
patient
experi
advers
effect
ae
antibiot
frequent
gener
popul
describ
ae
pattern
patient
attend
cf
centr
protocol
rapid
intraven
iv
antibiot
desensitis
employ
altern
treatment
avail
method
januari
decemb
patient
treat
iv
antibiot
cephalosporin
carbapenem
glycopeptid
fluoroquinolon
associ
aminoglycosid
cf
patient
airway
colonis
staphylococcu
aureu
n
pseudomona
aeruginosa
n
alcaligen
xylosoxidan
n
methicillinresist
aureu
n
burkolderia
cepacia
n
maltophilia
n
sinc
patient
colonis
one
bacteria
absolut
number
higher
overal
proport
patient
ae
altern
antibiot
treatment
prick
intraderm
skin
test
nativ
drug
carri
desensitis
begin
administ
iv
lower
concentr
antibiot
concentr
neg
intraderm
test
dose
subsequ
infus
use
washout
dose
dose
increas
time
therapeut
dose
reach
take
h
result
sixteen
present
ae
ceftazidim
two
carbapenem
three
vancomycin
one
aztreonam
one
ciprofloxacin
tabl
eleven
patient
experienc
ae
two
cours
antibiot
desensitis
carri
nine
patient
altern
antibiot
therapi
avail
well
toler
seven
case
tabl
object
antimicrobi
agent
exert
effect
insid
interstiti
space
site
mani
infect
recent
microdialysi
appli
cortic
cancel
bone
evalu
gentamicin
principl
microdialysi
introduc
semiperm
membran
bone
perfus
liquid
thu
enabl
dynam
measur
made
aim
investig
measur
pharmacokinet
gentacol
spong
bone
tissu
techniqu
microdialysi
method
nine
pig
randomis
either
wet
dri
applic
gentacol
spong
cm
bone
marrow
tibia
two
cathet
insert
cancel
bone
tissu
one
cm
cm
one
cm
apart
aim
locat
spong
gentacol
spong
implant
wet
applic
defin
spong
wet
ml
blood
dri
applic
defin
usual
surgic
procedur
concentr
gentamicin
measur
serum
microdialys
abbott
drug
analys
data
present
median
rang
rank
sum
test
perform
statist
analysi
pvalu
consid
signific
pharmacokinet
measur
present
area
curv
peak
concentr
c
peak
conclus
first
studi
appli
microdialysi
pharmacokinet
measur
local
implant
distribut
local
appli
antibiot
bone
tissu
difficult
measur
small
sampl
size
preclud
detail
analysi
noteworthi
previou
found
variat
distribut
gentamicin
gentacol
spong
reproduc
work
seem
neither
applic
distanc
signific
impact
initi
pharmacokinet
gentacol
bone
tissu
object
previou
studi
demonstr
abil
levofloxacinimipenem
prevent
emerg
resist
among
clinic
isol
p
aeruginosa
twocompart
vitro
pharmacodynam
model
ivpm
studi
design
analys
levofloxacinimipenem
strain
p
aeruginosa
alreadi
lack
suscept
one
drug
differ
effluxor
oprdassoci
mechan
method
strain
use
studi
includ
four
levofloxacinnonsuscept
strain
overexpress
mexaboprm
mexcdoprj
mexefoprn
mexxi
one
imipenemresist
strain
lack
oprd
one
dualresist
strain
overexpress
mexxi
lack
oprd
logphas
cultur
cfuml
inocul
peripher
compart
ivpm
treat
simul
dose
mg
levofloxacin
mg
imipenem
levofloxacinimipenem
levofloxacin
dose
h
imipenem
h
dose
adjust
account
protein
bind
pharmacodynam
evalu
h
result
mexaboprm
mexcdoprj
mexefoprn
overexpress
mutant
levofloxacinimipenem
achiev
total
kill
one
strain
erad
two
strain
furthermor
levofloxacinimipenem
prevent
emerg
resist
observ
drug
alon
levofloxacinimipenem
also
prevent
emerg
levofloxacin
resist
achiev
erad
strain
lack
oprd
although
levofloxacinimipenem
initi
achiev
log
kill
two
mexxi
mutant
could
prevent
emerg
resist
conclus
data
support
levofloxacinimipenem
effect
combin
treat
p
aeruginosa
prevent
emerg
resist
therapi
data
warrant
evalu
levofloxacinimipenem
p
aeruginosa
new
extend
releas
formul
ciprofloxacin
cipro
xr
design
daili
administr
treatment
urinari
tract
infect
uti
aim
studi
compar
plasma
urin
concentr
pharmacokinet
paramet
levofloxacin
lvx
method
randomis
crossov
studi
volunt
six
male
six
femal
receiv
singl
oral
dose
mg
cipro
xr
mg
lvx
assess
concentr
highpressur
liquid
chromatographi
plasma
urinari
excret
interv
h
follow
pharmacokinet
paramet
studi
cmax
tmax
auc
cltot
clren
vdss
maxim
urinari
concentr
umax
urinari
excret
ue
result
fluoroquinolon
toler
well
mean
pharmacokinet
paramet
shown
tabl
median
cumul
level
renal
excret
administ
dose
parent
drug
ciprofloxacin
rang
mean
ae
sd
ae
levofloxacin
rang
mean
ae
sd
ae
cmax
auc
ue
statist
significantli
higher
lvx
phase
wherea
pharmacokinet
indic
except
statist
significantli
higher
cipro
xr
phase
conclus
oral
administr
cipro
xr
mg
lvx
mg
cmax
auc
plasma
significantli
higher
lvx
phase
renal
excret
milligram
cipro
xr
mg
daili
howev
equival
lvx
mg
overal
compar
urinari
concentr
area
urinari
concentr
reach
drug
therefor
assum
two
dose
investig
consid
equival
treatment
uti
failur
detect
emerg
resist
moxifloxacin
aucmic
ratio
bacteroid
fragili
bf
clostridium
perfringen
cp
gramposit
anaerob
cocci
gpac
vitro
pharmacokinet
pk
model
object
moxifloxacin
moxi
vitro
activ
mani
anaerob
human
pk
may
clinic
use
anaerob
infect
perform
dose
rang
studi
assess
emerg
resist
human
volunt
brainheart
infus
broth
use
nutrient
coloni
count
done
appropri
time
interv
concentr
levofloxacin
determin
bioassay
use
k
pneumonia
test
organ
experi
done
triplic
result
data
three
parallel
experi
match
suffici
demonstr
reproduc
vitro
model
experi
simul
oral
dose
mg
levofloxacin
p
aeruginosa
reduc
five
six
order
magnitud
within
h
regrowth
seen
h
bacteri
count
h
still
three
order
magnitud
inoculum
resist
subpopul
seen
order
mutat
rate
elimin
h
reappear
mg
dose
gave
similar
result
reduct
cell
count
five
order
magnitud
h
h
cell
count
inoculum
howev
resist
mutant
persist
reach
cell
count
five
order
inoculum
h
pneumonia
reduct
bacteri
count
went
continu
three
order
magnitud
within
h
resist
mutant
aris
real
differ
dose
schedul
conclus
result
demonstr
levofloxacin
suffici
dose
abl
reduc
actual
bacteri
count
epitheli
line
fluid
three
six
order
magnitud
prevent
select
resist
mutant
gramposit
gramneg
bacteria
thu
drug
seem
use
treatment
nosocomi
pneumonia
background
salmonella
import
public
health
concern
especi
third
world
countri
ampicillin
tmpsmx
chloramphenicol
longer
provid
reliabl
coverag
mani
area
report
resist
emerg
older
quinolon
date
studi
evalu
pharmacokineticspharmacodynam
pkpd
quinolon
vs
salmonella
typhi
conduct
method
vitro
pd
model
ivpm
simul
human
gatifloxacin
gat
pk
use
determin
pkpd
measur
strongli
associ
drug
respons
relationship
exposur
respons
typhi
strain
gat
mic
mgl
drug
respons
express
log
ratio
h
area
bacteri
kill
curv
drug
growth
control
gc
regimen
qd
bid
ci
produc
wide
rang
free
f
mic
peak
mic
auc
mic
ratio
gat
studi
use
pkpd
target
deriv
ivpm
current
nccl
suscept
breakpoint
ciprofloxacin
cip
vs
typhi
mont
carlo
simul
mc
perform
assess
pkpd
target
attain
recommend
dose
select
quinolon
pk
obtain
normal
healthi
volunt
result
use
nonlinear
regress
sigmoid
inhibitori
emax
model
fit
log
gc
pkpd
measur
see
figur
fauc
mic
correl
best
gat
efficaci
r
peak
mic
also
correl
gat
efficaci
r
mic
r
model
estim
emax
auc
hill
constant
respect
assum
least
ivpm
emax
would
translat
good
activ
vivo
gat
fauc
mic
ratio
mgl
h
identifi
pkpd
target
per
cent
pkpd
target
attain
gat
levofloxacin
lev
ofloxacin
ofl
cip
base
simul
healthi
subject
receiv
standard
dose
regimen
rang
typhi
mic
mgl
shown
tabl
conclus
fauc
mic
ratio
mgl
h
associ
optim
effect
typhi
find
consist
quinolon
pkpd
target
measur
report
gramneg
enter
mc
result
suggest
low
per
cent
pkpd
target
attain
typhi
strain
quinolon
mic
mg
l
given
current
nccl
suscept
breakpoint
mgl
cip
vs
typhi
data
suggest
need
reassess
suscept
breakpoint
result
human
serum
promot
growth
drugfre
control
approxim
log
cfuml
reduc
bactericid
activ
agent
studi
howev
data
normalis
subtract
effect
serum
promot
growth
bactericid
activ
agent
gram
enhanc
presenc
serum
irrespect
protein
bind
also
mxf
exhibit
concentr
depend
bactericid
effect
pathogen
rang
concentr
studi
typic
bactericid
effect
blactam
could
increas
beyond
optim
bactericid
concentr
cla
reduc
cfu
gram
well
ineffect
hi
cfx
sa
strain
pneumonia
mic
mgl
initi
inoculum
approxim
cfuml
expos
amoxicillin
vitro
kinet
model
concentr
timeprofil
simul
human
serum
profil
xr
twice
daili
isol
also
expos
amoxicillin
concentr
timeprofil
correl
human
dosag
mg
twice
mg
three
time
daili
mg
three
time
daili
simul
halflif
h
repeat
sampl
taken
regularli
h
viabl
count
perform
result
xr
amoxicillin
profil
bacteri
erad
note
strain
mic
mgl
mic
experi
xr
strain
mic
mgl
mic
regrowth
occur
end
dose
interv
net
reduct
bacteri
count
h
leasteffect
dose
strain
mg
twice
daili
mic
respect
strain
mic
mg
l
none
regimen
abl
erad
strain
mic
mgl
although
initi
substanti
kill
note
enhanc
xr
profil
dose
conclus
enhanc
xr
profil
amoxicillin
effect
comparison
dose
regimen
erad
pneumonia
mic
mgl
strain
mic
mgl
reduct
bacteri
count
approxim
log
cfu
h
xr
regimen
regimen
result
static
effect
vitro
system
like
other
includ
potenti
synergist
effect
antibiot
immun
defenc
system
may
thu
reflect
situat
immunocompromis
host
rather
normal
patient
object
aim
studi
assess
pharmacodynam
profil
ciprofloxacin
cip
regard
strain
e
coli
firststep
mutant
method
evalu
nine
clinic
strain
e
coli
resist
nalidix
acid
suscept
cip
antibiogram
two
refer
strain
e
coli
suscept
nalidix
acid
na
mic
nalidix
acid
ofloxacin
levofloxacin
cip
evalu
use
etest
method
mutant
prevent
concentr
mpc
determin
appli
cfuml
organ
serial
dilut
antibioticconcentr
agar
plate
plate
incub
c
day
mpc
drug
lowest
concentr
capabl
inhibit
growth
organ
procedur
perform
triplic
ensur
reproduc
genotyp
sequenc
quinolon
resistancedetermin
region
gyra
parc
clinic
strain
mutant
bactericid
activ
determin
prepar
timekil
curv
cip
regard
three
strain
firststep
resist
mutant
strain
result
note
three
genotyp
strain
two
strain
mutat
mic
mgl
cip
mic
mgl
na
six
strain
gyra
mutat
codon
mic
mgl
cip
mic
mgl
na
three
strain
gyra
mutat
codon
parc
mutat
codon
mic
mgl
cip
mic
mgl
na
mpc
rang
first
genotyp
second
genotyp
mgl
third
genotyp
wild
strain
mutat
concentrationdepend
bactericid
activ
cip
observ
clinic
strain
gyra
mutat
firststep
resist
mutant
note
slow
bactericid
activ
cip
h
minimum
bactericid
activ
cip
rang
mic
conclus
cip
less
concentrationdepend
strain
gyra
mutat
object
prosthet
joint
infect
repres
infrequ
fear
complic
total
joint
arthroplasti
lead
substanti
postop
morbid
prosthesi
failur
case
death
moxifloxacin
new
fluoroquinolon
broad
antibacteri
spectrum
improv
activ
gram
posit
microorgan
anaerob
show
enhanc
potenc
methicillinsuscept
resist
isol
aureu
epidermidi
compar
older
fluoroquinolon
penetr
moxifloxacin
bone
still
assess
main
purpos
studi
determin
moxifloxacin
level
serum
bone
follow
oral
administr
singl
multipl
oral
dose
mg
drug
evalu
potenti
use
periop
orthopaed
prophylaxi
method
thirti
consecut
patient
undergo
routin
total
knee
arthroplasti
enrol
studi
background
levofloxacin
levo
advoc
least
activ
ciprofloxacin
cip
p
aeruginosa
accord
pharmacokineticpharmacodynam
paramet
aim
studi
assess
mutant
prevent
concentr
mpc
quinolon
two
differ
p
aeruginosa
popul
compar
pharmacokinet
paramet
respiratori
compart
method
studi
p
aeruginosa
isol
recov
respiratori
secret
patient
ventil
associ
pneumonia
admit
icu
hospit
cystic
fibrosi
cf
patient
mpc
defin
lowest
drug
concentr
preclud
bacteri
growth
h
determin
appli
cfuml
organ
serial
dilut
cip
levo
contain
plate
mic
determin
etest
result
p
aeruginosa
icu
patient
suscept
levo
mic
rang
lgml
cip
mic
rang
lgml
wherea
isol
cf
patient
suscept
levo
mic
lgml
cip
mic
lg
ml
respect
p
aeruginosa
icu
patient
levompc
rang
lgml
geometr
mean
lgml
higher
compar
cipmpc
rang
lgml
geometr
mean
lgml
mpc
higher
cf
popul
maintain
similar
differ
among
antibiot
cipmpc
rang
lgml
geometr
mean
lgml
levompc
rang
lgml
geometr
mean
lg
ml
compar
antipneumococc
effect
telithromycin
tel
clarithromycin
cla
pharmacodynam
differenti
suscept
pneumonia
studi
vitro
dynam
model
simul
human
pharmacokinet
method
pharmacokinet
data
report
human
studi
tel
cla
fit
twocompart
model
firstord
absorpt
ka
alpha
beta
h
respect
tel
h
respect
cla
base
analysi
time
cours
tel
cla
concentr
simul
pneumonia
atcc
mictlr
micclr
mgl
pneumonia
mictlr
micclr
mgl
expos
singl
dose
tel
mg
vs
two
dose
cla
mg
quantit
compar
antimicrobi
effect
area
control
curv
timekil
curv
abbc
calcul
result
distinct
dosedepend
antipneumococc
effect
tel
cla
term
minim
number
surviv
organ
effect
mg
tel
pneumonia
atcc
pronounc
mg
cla
differ
seen
pneumonia
similar
result
obtain
higher
dose
advantag
tel
seen
pneumonia
atcc
pneumonia
find
confirm
abbc
analysi
atcc
strain
larger
area
curv
auc
mic
ratio
cla
may
need
produc
abbc
similar
smaller
aucmic
tel
conclus
data
pharmacodynam
support
oncedaili
administr
mg
tel
treatment
infect
due
pneumonia
bactericid
activ
postantibiot
effect
clarithromycin
streptococcu
pneumonia
efflux
mechan
macrolid
resist
object
streptococcu
agalactia
dysgalactia
uberi
major
streptococc
caus
agent
bovin
mastiti
rapid
simultan
identif
speci
necessari
monitor
mastiti
caus
streptococci
kda
chaperonin
gene
recent
discov
agalactia
dysgalactia
uberi
strain
sequenc
goal
present
studi
develop
gene
base
pcr
approach
simultan
identif
streptococc
speci
method
total
strain
agalactia
dysgalactia
uberi
isol
dairi
cow
test
human
agalactia
strain
also
analys
bacteria
grown
toddhewitt
broth
sequenc
gene
origin
access
genbank
databas
dna
sampl
pcr
prepar
boil
one
two
bacteri
coloni
min
pcr
product
sequenc
use
abi
prism
perkinelm
sequenc
result
compar
analysi
nucleotid
sequenc
agalactia
dysgalactia
uberi
gene
reveal
certain
differ
speci
base
differ
three
pair
primer
design
pair
suggest
speciesspecif
pcr
analysi
amplif
fragment
expect
size
bp
obtain
agalactia
dysgalactia
uberi
strain
respect
human
bovin
agalactia
reveal
pcr
product
size
nucleotid
sequenc
agalactia
dysgalactia
uberi
amplif
fragment
determin
expect
speciesspecif
primer
demonstr
primer
use
multiplexpcr
simultan
identif
streptococc
speci
multiplexpcr
reveal
complet
correl
result
convent
pcr
neither
falseposit
falseneg
result
receiv
conclus
data
demonstr
gene
base
multiplexpcr
assay
effect
use
simultan
identif
agalactia
dysgalactia
uberi
strain
novel
approach
employ
analysi
milk
product
monitor
mastiti
work
support
slovak
combin
analysi
boxand
rapdpcr
pattern
reveal
uniqu
genet
type
eight
major
group
compris
three
six
isol
includ
singl
isol
strain
orphanag
moscow
ufa
khabarovsk
belong
one
major
clone
suggest
rapid
transmiss
close
commun
two
case
clonal
related
isol
geograph
distinct
center
kazan
moscow
saint
petersburg
voronezh
also
found
howev
multipl
genet
type
indic
resist
penicillin
acquir
numer
strain
conclus
combin
boxand
rapdpcr
suffici
discriminatori
power
allow
distinguish
penicillinnonsuscept
clone
penicillinresist
sp
isol
russian
dcc
orphanag
mostli
repres
genet
divers
popul
strain
clonal
transmiss
penicillinresist
clone
confirm
within
citi
also
geograph
distinct
area
method
total
high
vagin
swab
hv
women
rom
week
gestat
incub
nutrient
broth
first
hv
swab
incub
min
remain
hv
swab
incub
h
follow
incub
dna
extract
use
instagen
matrix
dna
kit
biorad
realtim
pcr
perform
use
lightcycl
instrument
roch
diagnost
oligonucleotid
primer
fluorescencelabel
hybridis
probe
use
specif
amplif
detect
fragment
cfb
gene
hv
also
examin
convent
cultur
plate
onto
islam
agar
incub
overnight
c
aerob
co
sensit
assay
examin
analys
dilut
overnight
broth
gb
specif
studi
test
differ
speci
streptococcu
assay
result
lightcycl
pcr
assay
abl
detect
gb
cfuml
nongb
isol
examin
neg
test
therebi
demonstr
specif
assay
first
hv
examin
four
posit
time
point
min
lightcycl
assay
convent
cultur
second
hv
eight
posit
lightcycl
six
posit
cultur
h
incub
follow
h
incub
sampl
posit
lightcycl
six
cultureposit
three
sampl
lightcyclerposit
overnight
incub
four
sampl
neg
cultur
lightcyclerposit
h
incub
two
cultureposit
sampl
lightcyclerposit
h
incub
indic
sampl
contain
low
number
gb
conclus
lightcycl
pcr
assay
specif
sensit
rapid
mean
detect
gb
hv
lightcycl
assay
sensit
convent
cultur
overnight
incub
increas
detect
rate
gb
howev
whether
clinic
signific
ie
woman
infect
colonis
requir
investig
gene
encod
lipoprotein
involv
metal
transport
adher
consid
possibl
virul
factor
attempt
clone
express
analysi
group
b
streptococc
gb
analogu
gene
famili
method
gb
strain
deriv
ia
serotyp
use
clone
adher
gene
analogu
pcr
primer
design
accord
conserv
region
gene
famili
studi
scaa
gene
use
sourc
origin
sequenc
dna
fragment
gb
scaa
analogu
amplifi
sequenc
use
fragment
probe
entir
sequenc
gb
scaa
analogu
determin
phage
librari
gene
sequenc
express
e
coli
result
entir
sequenc
scaa
gene
analogu
gb
clone
sequenc
deposit
gene
bank
gb
scaa
regulon
found
similar
one
group
streptococci
scaa
gene
locat
direct
proxim
atp
bind
protein
scac
similar
orient
neg
regul
scar
opposit
orient
central
portion
gb
scaa
clone
integr
vector
b
result
plasmid
use
gb
strain
transform
gb
transform
unabl
grow
like
parent
strain
liquid
media
form
clot
instead
typic
chain
express
substanti
differ
level
adher
gb
scaa
gene
clone
e
coli
system
express
employ
pqe
express
vector
system
howev
imposs
purifi
entir
protein
use
six
residu
locat
n
terminu
process
recombin
streptococc
lipoprotein
e
coli
order
obtain
matur
protein
clone
gb
scaa
start
region
encod
lipoprotein
cleavag
site
lxxc
purifi
matur
protein
kda
obtain
use
immunis
experi
mice
rabbit
possibl
usag
gb
scaa
protein
vaccin
gb
infect
discuss
conclus
novel
gb
gene
encod
put
metal
transport
adher
relat
lipoprotein
clone
express
e
coli
protein
might
import
gb
adher
human
epithelium
relationship
modular
structur
eucaryoticlik
serinethreonin
protein
kinas
stkp
streptococcu
pneumonia
function
p
pallova
l
prenosilova
l
novakova
p
branni
pragu
cz
object
main
object
work
determin
relationship
structur
function
eucaryoticlik
serthr
protein
kinas
stkp
pneumonia
ctermin
part
stkp
identifi
four
repeat
pasta
signatur
penicillinbind
protein
serinethreonin
kinas
associ
domain
propos
domain
could
bind
unlink
peptidoglycan
act
sensor
thu
stkp
might
involv
cellwal
biosynthesi
interact
pasta
domain
cell
wall
compon
pasta
domain
also
import
antibiot
resist
determin
penicillinbind
protein
method
determin
cellular
localis
stkp
prepar
epitopelabel
protein
kinas
stkp
fulllength
truncat
form
stkp
construct
correspond
mutant
creat
allel
exchang
result
fulllength
form
stkp
detect
membran
fraction
delet
ctermin
part
stkp
includ
put
transmembran
domain
result
presenc
mutant
form
stkp
exclus
cytoplasm
fraction
result
clearli
show
stkp
membraneassoci
protein
investig
influenc
delet
stkp
ctermin
modul
antibiot
suscept
pneumonia
mutant
strain
cytoplasm
stkp
show
increas
sensit
penicillin
g
vancomycin
antibiot
inhibit
cellwal
synthesi
addit
abil
mutant
strain
develop
state
natur
compet
measur
effici
transform
two
order
magnitud
lower
compar
wild
type
strain
conclus
result
indic
ctermin
part
stkp
act
sensor
activ
signal
pathway
control
stkp
protein
kinas
activ
identif
streptococci
speci
level
pyrosequenc
p
huovinen
j
jalava
object
object
studi
develop
molecular
method
inexpens
reliabl
simpl
identif
streptococc
speci
method
develop
method
identif
streptococci
base
pyrosequenc
techniqu
use
psq
system
biotageab
uppsala
sweden
two
hypervari
region
streptococc
rdna
analys
region
call
locat
close
terminu
rrna
gene
studi
signatur
sequenc
type
strain
differ
streptococc
speci
determin
first
step
method
perform
pcr
compris
region
sequenc
pcr
heatinactiv
streptococc
suspens
may
use
sampl
check
presenc
pcr
product
agaros
gel
sequenc
carri
sequenc
reaction
region
perform
separ
use
primer
specif
region
respect
result
sequenc
approxim
base
long
signatur
sequenc
region
streptococc
speci
except
differenti
two
speci
group
differenti
salivariu
vestibulari
thermophilu
well
bovi
lutetiensi
conclus
simpl
reliabl
fast
method
identif
vast
major
streptococc
speci
develop
whole
procedur
complet
singl
work
day
multilocu
sequenc
type
group
streptococci
london
hospit
object
group
streptococci
ga
collect
london
hospit
characteris
multilocu
sequenc
type
mlst
determin
ident
preval
clone
circul
set
london
ga
compar
strain
global
collect
ga
via
internet
access
mlst
databas
http
wwwmlstnet
method
mlst
sequenc
type
st
assign
isol
base
sequenc
intern
fragment
seven
housekeep
loci
emmtyp
defin
sequenc
central
emm
gene
isol
test
suscept
erythromycin
tetracyclin
result
juli
octob
clinic
isol
collect
person
includ
hospitalis
patient
outpati
attend
emerg
room
special
outpati
clinic
gp
fortyon
st
identifi
repres
singl
isol
eight
preval
type
among
ga
compar
mlst
databas
st
previous
identifi
although
six
differ
recognis
st
singl
locu
suggest
close
relat
resist
erythromycin
tetracyclin
seen
isol
respect
three
isol
resist
agent
resist
isol
includ
strain
distinct
st
five
st
repres
resist
suscept
isol
conclus
ga
strain
higher
emm
type
account
signific
proport
ga
isol
collect
studi
inform
may
import
ramif
emmdirect
vaccin
strategi
appear
resist
isol
associ
particular
clone
object
search
genom
sequenc
pneumonia
reveal
presenc
singl
eucaryoticlik
serthr
protein
kinas
gene
stkp
associ
gene
encod
serthr
protein
phosphatas
phpp
eucaryoticlik
protein
kinas
phosphatas
procaryot
coordin
process
differenti
pathogenesi
thu
stkp
phpp
may
play
role
pneumococc
pathogenesi
main
object
work
determin
target
protein
kinas
stkp
method
order
determin
function
stkp
prepar
delet
correspond
gene
pneumonia
pcr
ligat
mutagenesi
allel
exchang
identifi
gene
control
stkp
analys
transcript
profil
stkp
lossoffunct
mutant
dna
microarray
technolog
result
measur
transform
effici
natur
compet
develop
show
delet
stkp
gene
pneumonia
result
loss
genet
compet
transcript
analysi
reveal
stkpdepend
express
mani
potenti
target
loci
specif
strongli
upand
downregul
stkp
mutant
suggest
import
regulatori
role
stkp
pneumonia
data
obtain
transcriptom
map
extend
proteom
studi
mass
spectrometr
sequenc
use
identifi
put
target
posttransl
modif
conclus
conclus
gene
whose
transcript
induc
repress
pneumonia
stkp
delet
mutant
identifi
proteom
studi
mass
spectrometri
use
confirm
result
object
object
studi
investig
use
pyrosequenc
analysi
variabl
region
within
rnpb
gene
speciesspecif
target
identif
bacteria
within
streptococcu
genu
method
rnpb
gene
univers
present
bacteri
speci
encod
subunit
rnasep
enzym
comparison
rnpb
dna
sequenc
shown
use
phylogenet
studi
bacteri
genera
et
al
short
region
gene
use
target
pyrosequenc
rapid
realtim
method
sequencingbysynthesi
result
rnpb
dna
sequenc
streptococc
speci
align
identifi
target
region
pcr
dna
sequenc
rnpb
region
chosen
target
region
highli
variabl
flank
conserv
dna
region
target
region
amplifi
pcr
use
dna
prepar
type
strain
well
clinic
isol
templat
amplicon
analys
pyrosequenc
obtain
dna
sequenc
base
length
found
suffici
inform
identif
speci
blast
search
local
databas
genbank
limit
number
close
relat
speci
could
discrimin
analysi
eg
salivariu
vestibulari
pair
could
separ
correct
speci
level
sequenc
analysi
second
region
pcr
fragment
region
conclus
pyrosequenc
analysi
short
variabl
region
within
rnpb
gene
valuabl
tool
highresolut
speci
identif
streptococci
qiagen
germani
mlst
carri
describ
mlst
websit
http
neisseriamlstnet
first
amplif
seven
allel
abcz
adk
aro
fumc
gdh
pdhc
pgm
perform
amplitron
ii
thermocycl
use
hot
start
second
amplif
allel
perform
amplifi
product
follow
purif
product
peg
sequenc
reaction
perform
pcr
tube
bigdy
termin
cycl
sequenc
kit
pe
biosystem
subsequ
analys
abi
prism
autom
dna
sequenc
perkin
elmer
final
sequenc
locu
determin
use
lasergen
softwar
packag
dnastar
madison
wi
usa
import
diagnos
infect
rapidli
order
start
appropri
treatment
soon
possibl
continu
treatment
alreadi
initi
latex
agglutin
la
pcr
method
direct
quick
noncultur
method
la
immunolog
techniqu
detect
solubl
antigen
pcr
method
detect
presenc
dna
pathogen
focus
project
correl
posit
result
la
pcr
variou
clinic
materi
time
develop
method
assess
patient
hospitalis
clinic
infecti
diseas
invas
meningococc
diseas
cerebrospin
fluid
csf
serum
urin
collect
first
seventh
day
hospitalis
use
two
kit
la
slidex
kit
csf
pasteur
mening
kit
biolog
materi
dna
isol
qiagen
kit
pcr
method
use
pcr
product
detect
gel
electrophoresi
test
csf
serum
urin
sampl
result
csf
la
pcr
result
posit
day
admiss
onset
antibiot
therapi
ao
atb
patient
subsequ
csf
test
perform
six
posit
neg
result
pcr
la
neg
case
serum
la
pcr
result
posit
day
admiss
ao
atb
sampl
collect
four
day
ao
atb
result
la
pcr
neg
urin
la
result
posit
day
admiss
sampl
collect
next
day
result
posit
lower
percentag
conclus
result
method
depend
concentr
pathogen
clinic
materi
la
less
sensit
pcr
la
bring
posit
result
subsequ
csf
test
pcr
result
posit
correl
result
pcr
la
serum
technolog
base
probe
tile
strategi
four
probe
use
interrog
central
nucleotid
object
design
customseq
microarray
genotyp
characteris
neisseria
meningitidi
use
combin
dna
sequenc
four
gene
target
predic
genogroup
genotyp
genosubtyp
method
array
design
use
guidelin
affymetrix
corpor
genogroup
align
avail
ctra
siad
gene
sequenc
perform
eight
fragment
total
kbp
identifi
could
predict
genogroup
b
c
h
x
z
genotyp
typic
base
sequenc
four
porb
gene
variabl
region
vr
encod
outer
membran
protein
divid
class
sequenc
includ
microarray
base
sacchi
et
al
multipl
sequenc
class
align
new
variant
identifi
sequenc
total
kbp
genosubtyp
typic
base
sequenc
two
pora
vr
pora
variant
sequenc
avail
http
wwwneisseriaorg
within
vr
align
variantdefin
sequenc
identifi
sequenc
total
kbp
seventyf
meningococc
isol
divers
serogroup
serotyp
serosubtyp
genotyp
test
system
data
analysi
perform
use
genechip
dna
analysi
softwar
result
customseq
microarray
could
use
predict
serogroup
serotyp
serosubtyp
genosubtyp
concord
previou
pora
genosubtyp
capillarybas
sequenc
data
sampl
newli
genotyp
porb
conclus
first
applic
customseq
technolog
microbi
type
provid
dna
sequenc
data
singl
pcr
product
target
advantag
convent
capillarybas
sequenc
pora
porb
gene
current
requir
multipl
sequenc
reaction
genotyp
data
complement
current
phenotyp
type
scheme
proport
isol
type
limit
number
monoclon
antibodi
prototyp
could
appli
organ
extens
sequenc
data
requir
type
recent
emerg
virul
clone
neisseria
meningitidi
decreas
suscept
penicillin
itali
p
stefanelli
c
fazio
neri
sofia
p
mastrantonio
rome
object
great
increas
case
due
neisseria
meningitidi
phenotyp
decreas
suscept
penicillin
peni
occur
itali
sinc
peni
meningococci
analys
mlst
pfge
verifi
whether
increas
number
case
phenotyp
correl
emerg
singl
clone
readili
spread
countri
method
phenotyp
characteris
obtain
defin
serogroup
serosubtyp
penicillin
suscept
etest
method
molecular
analysi
pena
gene
carri
strain
addit
new
approach
realtimepcr
recent
set
appli
pfge
perform
digest
chromosom
dna
nhei
bglii
mlst
sequenc
gene
fragment
housekeep
gene
describ
http
neisseriaorgnm
typingmlst
result
among
serogroup
c
meningococci
isol
sinc
belong
phenotyp
interestingli
major
show
decreas
suscept
penicillin
mic
mcgml
spread
meningococci
remark
first
month
twice
mani
isol
compar
previou
year
accord
mlst
websit
data
peni
meningococci
ident
assign
cluster
dna
macrorestrict
fragment
gener
nhei
analys
pfge
show
one
main
pulsetyp
pta
two
subclon
minor
differ
name
bglii
use
strain
show
pt
frequent
pt
pta
seem
ident
fingerprint
pattern
describ
arreaza
et
al
j
med
microbiol
possibl
hypothesis
clone
import
differ
spanish
one
abl
caus
meningococc
invas
diseas
age
group
conclus
find
unambiguosli
confirm
increas
mening
caus
itali
n
meningitidi
caus
spread
singl
emerg
clone
belong
hypervirul
cluster
moreov
also
import
underlin
direct
relationship
increas
serogroup
c
strain
itali
eightfold
increas
peni
meningoccci
result
spread
singl
virul
clone
object
sinc
octob
portug
new
laboratori
surveil
system
meningococc
diseas
viglabmd
institut
receiv
n
meningitidi
strain
nation
hospit
lab
network
octob
novemb
major
case
meningococc
diseas
due
serogroup
b
n
meningitid
also
previou
serotyp
subtyp
n
meningitid
strain
show
phenotyp
frequent
isol
strain
cerebrospin
fluid
csf
blood
epidemiolog
propos
use
molecular
techniqu
differenti
strain
antigen
undistinguish
admit
possibl
nonexpress
serosubtypespecif
antigen
determin
also
includ
studi
strain
nst
nonsero
subtyp
express
determin
variabl
region
class
outermembran
protein
method
strain
potenti
antigen
profil
submit
molecular
characteris
pulsedfield
gel
electrophoresi
pfge
use
enzym
bgl
restrict
profil
analys
bionumer
softwar
applic
result
found
strain
potenti
antigen
type
submit
pfge
eleven
differ
pfge
pattern
found
strain
studi
conclus
consid
divers
puls
field
type
studi
strain
geograph
distribut
identifi
focu
outbreak
period
studi
object
invas
meningococc
infect
major
caus
sudden
death
neisseria
meningitidi
distinguish
bacteria
also
involv
waterhousefriderichsen
syndrom
wf
due
rapid
develop
infect
antemortem
cultur
sometim
taken
establish
aetiolog
need
howev
unreli
postmortem
cultur
molecular
diagnosi
need
aim
studi
investig
presenc
meningococcu
formalinfix
tissu
legal
sudden
death
realtim
pcr
assay
method
microbiolog
histopatholog
analys
legal
autopsi
adult
wf
perform
possibl
malpractic
investig
formalinfix
heart
liver
lung
kidney
supraadren
gland
avail
sampl
dna
extract
parafinembed
section
tissu
perform
mini
kit
extract
system
qiagen
detect
ctra
gene
target
specif
n
meningitidi
accomplish
realtim
pcr
assay
use
mgbprobe
develop
abi
sequenc
detect
system
posterior
serogroup
perform
amplif
group
specif
siad
b
c
gene
realtim
pcr
assay
perform
twice
sensibl
specif
studi
also
carri
evalu
pcr
assay
postmortem
sampl
result
posit
realtim
pcr
result
ctra
obtain
heart
liver
lung
kidney
sampl
ct
cycl
number
reach
baselin
threshold
valu
serogroup
b
detect
siad
pcr
assay
contrari
postmortem
haemocultur
yield
contamin
ctra
primer
set
amplifi
dna
meningococc
serogroup
b
c
crossreact
bacteri
dna
extract
test
conclus
reliabl
microbiolog
identif
particularli
import
legal
sudden
death
due
meningococcu
distinguish
bacteria
report
detect
meningococcu
realtim
pcr
paraffinembed
formalinfix
tissu
legal
autopsi
wf
case
meningococcu
realtim
pcr
perform
formalinfix
tissu
may
great
help
diagnosi
fulmin
death
sampl
avail
object
h
influenza
type
b
hib
strain
isol
invas
diseas
gener
possess
duplic
capsul
cap
b
locu
amplif
five
copi
report
propos
mechan
evad
host
defenc
verifi
amplif
cap
b
locu
involv
vaccin
failur
determin
number
copi
cap
b
locu
hib
isol
true
vaccin
failur
tvf
agematch
control
method
total
invas
hib
strain
isol
infant
children
uk
republ
ireland
test
patient
tvf
agematch
control
copi
number
cap
b
locu
determin
southern
blot
analysi
use
probe
bp
amplicon
capsul
type
bspecif
obtain
pcr
hib
strain
eagan
kpni
smai
site
flank
cap
b
locu
copi
number
estim
size
restrict
fragment
obtain
follow
digest
chromosom
enzym
dna
fragment
twocopi
strain
expect
approxim
kbp
strain
three
copi
locu
featur
fragment
increas
size
kbp
result
isol
tvf
control
group
exhibit
hybridis
signal
expect
posit
twocopi
arrang
cap
b
locu
howev
besid
kbp
band
sever
isol
contain
twocopi
arrang
show
strong
hybridis
signal
molecular
weight
higher
kbp
indic
presenc
multipl
copi
three
four
five
repeat
locu
significantli
greater
proport
isol
patient
tvf
contain
multipl
copi
compar
strain
control
fact
strain
harbour
three
copi
locu
tvf
group
vs
number
strain
nst
among
control
p
interestingli
presenc
multipl
copi
significantli
associ
greater
proport
clinic
present
mening
children
belong
tvf
control
group
conclus
result
show
number
multipl
copi
strain
found
among
tvf
significantli
higher
control
group
although
case
invas
hib
diseas
vaccin
children
gener
relat
clinic
immunolog
condit
host
use
less
immunogen
vaccin
data
suggest
amplif
cap
b
locu
may
also
involv
object
otiti
media
effus
ome
one
major
caus
hear
loss
childhood
known
h
influenza
pneumonia
catarrhali
consid
chief
pathogen
ome
children
bacteri
mening
still
diseas
high
morbid
mortal
rate
despit
effect
antimicrobi
therapi
h
influenza
pneumonia
neisseria
meningitidi
respons
case
microorgan
bacteri
mening
ome
fastidi
characterist
convent
cultur
abl
make
clear
cascad
identif
therefor
pcr
appli
detect
bacteri
dna
cerebrospin
fluid
csf
middl
ear
effus
mee
specimen
evalu
signific
diagnost
valu
pcr
techniqu
compar
convent
cultur
method
gold
standard
method
total
csf
mee
sampl
collect
meningitisand
omesuspect
children
respect
test
convent
cultur
pcr
method
result
one
csf
pneumonia
three
mee
one
h
influenza
nonb
two
catarrhali
sampl
cultur
posit
pcr
reveal
genom
dna
sequenc
pneumonia
csf
sampl
eight
three
h
influenza
three
catarrhali
two
yield
pneumonia
catarrhali
other
mee
sampl
sensit
specif
posit
predict
valu
neg
predict
valu
correl
rate
total
studi
sampl
csf
mee
respect
conclus
conclud
pcr
techniqu
sensit
rapid
appropri
method
convent
cultur
detect
three
common
microorgan
lead
mening
ome
children
background
sinc
global
threat
sever
acut
respiratori
syndrom
sar
outbreak
origin
describ
sever
atyp
pneumonia
guangdong
provinc
china
success
contain
earli
juli
mani
countri
remain
vigil
resurg
sar
investig
caus
role
sar
coronaviru
sarscov
atyp
pathogen
communityacquir
pneumonia
cap
postoutbreak
period
sever
acut
respiratori
syndrom
sar
new
respiratori
infect
report
sever
countri
around
world
recognis
new
type
atyp
pneumonia
infect
lung
caus
new
strain
coronaviru
sarscov
sar
kill
least
peopl
infect
worldwid
sinc
outbreak
china
guangdong
provinc
late
molecular
amplif
emerg
power
technolog
specif
sensit
detect
viru
howev
use
new
technolog
routin
laboratori
requir
rapid
easytoperform
afford
detect
method
analysi
agaros
gel
timeconsum
exclud
falseposit
product
altern
specif
detect
method
time
labourconsum
elisa
requir
expens
equip
realtim
amplif
order
perform
easi
specif
detect
amplifi
gene
product
set
test
new
detect
technolog
oligochromatographi
intern
probe
nucleic
acid
sequenc
detect
conjug
collod
gold
particl
conjug
pad
contain
dri
conjug
place
overlap
membran
chromatograph
stick
antihapten
antibodi
coat
amplif
carri
haptenlabel
primer
detect
perform
dip
oligochromatograph
stick
amplifi
solut
migrat
stick
amplicon
react
colloid
goldconjugu
probe
probeamplicon
complex
accumul
line
antihapten
antibodi
coat
give
rise
visibl
red
line
min
highli
sensit
rtpcr
detect
sarscov
develop
contain
intern
control
allow
test
absenc
pcr
inhibitor
amplifi
materi
detect
rtpcr
coupl
oligochromatograph
detect
compar
agaros
gel
electrophoresi
ethidium
bromid
stain
oligochromatographi
shall
probabl
becom
best
way
specif
detect
nucleic
acid
sequenc
molecular
amplif
process
rapid
specif
easi
handl
requir
specif
equip
anaplasma
seropreval
variat
two
hunt
period
overal
mean
roe
deer
found
anaplasma
posit
pcr
mark
season
variat
pcr
posit
roe
deer
found
two
hunt
period
vs
sequenc
reveal
besid
phagocytophilium
plati
two
roe
deer
coinfect
uncultur
eubacterium
aj
borrelia
seropreval
even
distribut
two
period
region
variat
tbe
seropreval
posit
anim
found
forest
district
conclus
find
confirm
roe
deer
denmark
commonli
infect
anaplasma
provid
evid
roe
deer
major
reservoir
anaplasma
borrelia
seropreval
denmark
increas
chang
distribut
last
decad
wherea
tbe
distribut
increas
limit
island
bornholm
object
variola
viru
belong
orthopoxvirida
famili
one
danger
biolog
agent
could
use
biolog
weapon
problem
associ
event
mainli
due
high
morbid
mortal
absenc
herd
immun
young
popul
difficulti
clinic
diagnosi
due
similar
exantemat
diseas
laboratori
diagnosi
crucial
increas
global
prepared
event
culturebas
method
applic
maximum
biosafeti
level
molecular
method
prefer
wide
applic
use
laboratori
higher
facil
avail
aim
establish
rapid
pcrbase
protocol
contemporari
detect
orthopoxvirus
vzv
hsv
relev
differenti
diagnosi
method
target
detect
orthopoxviru
dna
region
crmb
gene
common
variola
viru
old
world
orthopoxvirus
pathogen
human
vzv
hsv
target
orf
dna
polymeras
respect
suitabl
amplifi
fragment
rflp
sequenc
analysi
also
test
recognis
involv
viral
speci
result
three
primer
set
three
virus
select
show
high
sensit
specif
compat
common
amplif
condit
test
condit
select
valid
use
biolog
sampl
patient
show
herpesvir
infect
orthopoxvirus
laboratori
strain
includ
vaccinia
camelpox
cawpox
monkeypox
virus
result
indic
method
possibl
obtain
rapid
differenti
herpesvir
orthopoxvir
infect
use
common
amplif
run
furthermor
amplicon
obtain
phase
suitabl
molecular
analysi
allow
viru
identif
definit
laboratori
diagnosi
one
recipi
allogen
stc
hmpv
posit
year
old
patient
admit
day
sibl
hlaident
tcell
deplet
bmt
fever
bilater
lung
shadow
bronchoalveolar
lavag
bal
neg
fungal
bacteri
pathogen
npa
bal
neg
viral
pathogen
receiv
therapi
broad
spectrum
antibiot
antifung
progress
respiratori
failur
die
day
diagnosi
hmpv
pneumonia
obtain
retrospect
conclus
data
minim
estim
preval
hmpv
dual
crv
hmpv
infect
exclud
hmpv
common
among
children
hospitalis
rsvlike
diseas
account
present
rsv
although
hmpv
less
common
among
immunocompromis
patient
rsv
vs
associ
fatal
pneumonia
postsct
set
data
highlight
potenti
signific
morbid
mortal
associ
hmpv
infect
found
fluoroquinolon
effect
erythromycin
ld
treatment
time
apyrexia
hospit
stay
tend
shorter
patient
quinolon
although
small
number
patient
includ
allow
signific
differ
found
includ
case
ld
centr
spain
use
antibiot
present
studi
compar
evolut
patient
ld
treat
macrolid
fluoroquinolon
method
perform
prospect
observ
studi
patient
diagnos
legionella
urinari
antigen
patient
receiv
antibiot
h
start
studi
therapi
exclud
patient
divid
two
group
group
receiv
macrolid
erythromycinclarithromycin
group
receiv
fluoroquinolon
ofloxacinlevofloxacin
result
signific
differ
seen
two
group
regard
age
sex
smoke
alcohol
intak
underli
diseas
communityhospit
acquisit
time
onset
ld
symptom
start
antibiot
treatment
h
group
respect
p
time
apyrexia
significantli
longer
macrolid
group
vs
h
group
respect
p
differ
radiolog
clinic
complic
mortal
howev
trend
longer
hospit
stay
observ
group
vs
day
group
respect
p
conclus
fluoroquinolon
found
effect
erythromycin
treatment
ld
time
apyrexia
significantli
shorter
hospit
stay
tend
shorter
patient
fluoroquinolon
result
thirtyf
case
elig
northeastern
anatolia
southern
part
black
sea
region
deal
husbandri
mean
age
fiftythre
per
cent
case
histori
tick
bite
clinic
statu
case
defin
sever
age
geograph
resid
histori
tick
bite
mean
number
day
hospitalis
complaint
differ
mild
moder
case
sever
case
p
mean
length
stay
longer
among
sever
case
p
femal
sever
affect
male
rr
ci
p
decreas
haemoglobin
level
p
elev
ast
p
alt
p
ldh
p
astalt
ratio
p
common
among
sever
case
five
sever
case
given
ribavirin
therapi
accord
recommend
surviv
six
sever
case
receiv
ribavirin
therapi
one
die
overal
case
fatal
rate
cfr
lowest
rate
literatur
cfr
increas
among
sever
case
receiv
ribavirin
costeffect
assess
limit
sever
case
includ
drug
laboratori
hospit
expens
cost
infect
ribavirin
group
per
patient
exclud
outlier
wherea
per
patient
among
nonribavirin
group
conclus
cchf
report
turkey
although
epidem
report
neighbour
countri
conclus
oral
ribavirin
administ
sever
case
suspect
cchf
viru
infect
phenotyp
charact
aureu
strain
associ
case
toxic
shock
syndrom
czech
republ
object
czech
refer
laboratori
staphylococci
pay
attent
toxic
shock
syndrom
tss
sinc
diseas
emerg
seventynin
case
requir
clinic
record
diagnosi
confirm
toxinogen
screen
aureu
isol
document
laboratori
date
aim
studi
investig
relev
characterist
strain
method
product
enterotoxin
b
c
e
detect
microslidegel
diffus
test
use
bergdol
antisera
rpla
method
denka
seiken
kit
type
b
c
use
sinc
product
alpha
beta
deltahaemolysin
detect
base
either
synergi
antagon
betahaemolysin
intermediu
standard
strain
blood
agar
plate
mix
atmospher
phage
type
perform
standard
method
use
intern
set
phage
phl
london
resist
antibiot
test
disk
diffus
method
oxoid
result
aetiolog
agent
eight
case
menstrual
form
tss
aureu
strain
product
mostli
parallel
enterotoxin
toxigen
patient
surviv
case
tss
complic
follow
staphylococc
infect
infect
injuri
wound
case
postop
hospit
infect
infect
scald
burn
fatal
outcom
report
case
ie
three
patient
age
year
two
patient
tsslike
complic
staphylococc
endocard
patient
account
signific
lethal
rate
mani
strain
produc
combin
enterotoxin
type
strain
produc
consider
amount
follow
enterotoxin
strain
b
c
two
strain
produc
type
c
b
c
object
genu
acinetobact
current
consist
genom
speci
number
yet
unclassifi
strain
aim
present
studi
classifi
haemolyt
acinetobact
strain
unknown
taxonom
statu
isol
mostli
human
clinic
specimen
method
twentyeight
haemolyt
strain
could
identifi
belong
known
genom
speci
studi
phenotyp
analysi
amplifi
rdna
restrict
analysi
ardra
aflp
fingerprint
rdna
compar
sequenc
analysi
type
refer
strain
known
acinetobact
genom
speci
includ
result
use
polyphas
approach
investig
strain
classifi
two
wellsepar
phenet
group
term
phenon
n
phenon
n
five
isol
remain
ungroup
two
phenon
contain
nonglucoseacidifi
strain
show
ident
highli
similar
phenotyp
properti
ardra
profil
form
distinct
aflp
cluster
similar
level
gener
speci
delin
level
addit
rdna
sequenc
analysi
three
two
strain
phenon
respect
indic
group
form
two
separ
lineag
within
genu
acinetobact
phenon
could
distinguish
phenotyp
known
genom
speci
strain
phenon
isol
exclus
human
clinic
specimen
wherea
phenon
strain
origin
human
n
equin
n
clinic
specimen
hospit
environ
staff
n
soil
n
human
clinic
specimen
mostli
repres
tracheal
aspir
hospitalis
patient
conclus
studi
shown
unclassifi
haemolyt
strain
belong
two
phenon
distinct
describ
genom
speci
genu
acinetobact
phenon
probabl
repres
two
novel
speci
indic
present
result
partial
dnadna
reassoci
data
avail
previou
taxonom
studi
presenc
stx
eaea
hlya
gene
confirm
pcr
bglucuronidas
activ
motil
also
test
part
casecontrol
studi
conduct
arlv
faecal
specimen
rest
farmer
famili
cattl
collect
investig
initi
identifi
sourc
contribut
factor
determin
extent
outbreak
stool
specimen
brother
patient
two
faecal
sampl
two
cattl
one
calf
one
bull
also
identifi
sf
stec
four
stec
isol
carri
virul
gene
stx
eaea
hlya
characteris
autom
ribotyp
use
ecori
restrict
enzym
pulsedfield
gel
electrophoresi
pfge
xbai
restrict
enzym
pattern
four
strain
indistinguish
type
method
sf
vtec
strain
previous
discov
germani
czech
republ
conclus
genuin
austrian
case
vtec
furthermor
resembl
first
case
strain
document
transmiss
anim
contact
illustr
hazard
associ
anim
contact
underlin
import
microbiolog
diagnost
approach
design
detect
sf
vtec
strain
normal
miss
method
sole
reli
sorbitolmac
conkey
agar
plate
thu
stool
specimen
patient
hu
also
young
children
least
test
presenc
shiga
toxin
object
carbapenem
resist
e
cloaca
unusu
describ
strain
porin
alter
combin
hyperproduct
chromosom
cephalosporinas
strain
produc
class
carbapenemhydrolys
nonmetallobetalactamas
nmca
betalactamas
strain
produc
betalactamas
recent
class
b
metallobetalactamas
mbl
report
imipenemresist
e
cloaca
strain
isol
korea
carri
integron
e
cloaca
strain
imipenem
mic
mgl
isol
tertiari
care
hospit
athen
greec
blood
cultur
hospitalis
patient
strain
demonstr
posit
edtadisc
synergi
test
studi
carbapenemas
product
method
e
cloaca
isol
blood
cultur
patient
suffer
fournier
gangren
suscept
test
perform
disk
diffus
techniqu
mic
determin
broth
microdilut
method
sensititr
ltd
west
sussex
uk
accord
nccl
guidelin
edtadisc
synergi
test
use
screen
mbl
product
betalactamas
detect
isoelectr
focus
ief
presenc
mbl
gene
determin
pcr
follow
set
primer
vimf
vimb
sequenc
clone
pcr
product
perform
mwgthe
genom
compani
result
isol
resist
aminopenicillin
cephalosporin
monobactam
reduc
suscept
imipenem
meropenem
mic
mgl
respect
demonstr
posit
edtadisc
synergi
test
ief
identifi
betalactamas
pi
probabl
correspond
chromosom
ampc
cephalosporinas
e
cloaca
band
pi
visibl
sequenc
clone
pcr
product
identifi
conclus
best
knowledg
first
report
presenc
mbl
e
cloaca
spread
mbl
enterobacteriacea
becom
grate
concern
greec
also
report
e
coli
k
pneumonia
isol
spread
could
compromis
futur
use
carbapenem
treatment
seriou
infect
caus
gramneg
bacilli
requir
attent
ever
compar
antibiot
resist
pattern
delin
clonal
divers
transmiss
pattern
plasmid
profil
reppcr
pfge
rapd
analysi
enterobact
cloaca
strain
isol
differ
environ
method
sixteen
e
cloaca
strain
cardiovascular
devic
insert
patient
seven
e
cloaca
strain
fresh
pollut
water
studi
antimicrobi
suscept
nccl
disc
diffus
method
doubledisc
induct
disc
diffus
test
plasmid
dna
profil
reppcr
fingerprint
dna
macrorestrict
xbai
endonucleas
rapd
use
primer
pfge
rapd
pattern
visual
compar
clonal
group
variant
use
upgma
algorithm
comput
ntsi
program
result
hospit
isol
esbl
produc
suscept
inhibitor
intermedi
suscept
third
gener
cephalosporin
suscept
quinolon
aminoglicosid
imipenem
aquat
strain
express
induc
betalactamas
phenotyp
resist
ampicillin
amoxicillinclavulan
acid
chloramphenicol
tetracyclin
cephalosporin
aminoglycosid
quinolon
plasmid
dna
profil
analysi
show
variabl
number
plasmid
rang
kpb
clinic
aquat
isol
chromosom
dna
digest
xbai
produc
averag
fragment
rang
kb
nine
epidemiolog
relat
strain
classifi
one
cluster
reppcr
rapd
inform
profil
obtain
pfge
six
nine
strain
classifi
one
cluster
wherea
remain
three
strain
relat
clonal
strain
differ
detect
two
cluster
aquat
strain
cluster
b
five
subtyp
cluster
c
two
subtyp
accord
upgma
criteria
reppcr
rapd
pfge
profil
conclus
esbl
strain
isol
hospitalis
patient
belong
clone
induc
betalactamas
produc
strain
isol
differ
aquat
sourc
belong
two
clone
conclud
found
three
spatial
cluster
unrel
isol
possibl
clonal
related
among
rapd
pfge
suitabl
molecular
type
e
cloaca
isol
intraand
extrahospit
origin
introduct
acinetobact
baumannii
import
nosocomi
pathogen
caus
infect
immunocompromis
patient
artifici
ventil
treatment
often
complic
multiresist
carbapenem
becom
drug
choic
report
resist
increas
target
modif
andor
porin
loss
caus
resist
carbapenemas
molecular
class
b
imp
vim
seem
frequent
report
spread
two
clone
baumannii
across
southern
england
method
carbapenemresist
acinetobact
receiv
mic
confirm
type
refer
laboratori
identifi
standard
method
type
pfge
mic
determin
etest
agar
dilut
gene
encod
carbapenemas
sought
pcr
primer
blaimp
blavim
pcr
product
sequenc
strand
chromosom
dna
digest
ecori
ecorv
restrict
endonucleas
probe
use
dnadna
hybridis
result
gene
detect
pcr
repres
two
clone
sequenc
indic
enzym
classic
dnadna
hybridis
indic
enzym
chromosom
encod
clone
clone
distinct
pfge
profil
contain
sever
pfge
variant
clone
differ
origin
baumannii
report
scotland
eleven
hospit
submit
sampl
clone
three
submit
sampl
clone
one
submit
isol
belong
clone
affect
hospit
southern
england
isol
carbapenemresist
also
multiresist
ciprofloxacin
aminoglycosid
betalactam
includ
sulbactam
consist
sensit
polymyxin
mic
mgl
minocyclin
mic
mgl
conclus
two
baumannii
clone
produc
betalactamas
spread
multipl
hospit
southern
england
simultan
spread
unrel
similarli
resist
clone
disturb
ps
aeruginosa
resist
imipenem
imipenem
resist
baumannii
isol
irab
also
resist
meropenem
gentamicin
cefotaxim
ceftazidim
amikacin
imipenem
resist
ps
aeruginosa
isol
irp
resist
gentamicin
cefotaxim
ceftazidim
meropenem
amikacin
use
rapd
techniqu
four
distinct
genotyp
identifi
among
irab
isol
clone
account
isol
clone
ii
isol
clone
iii
three
isol
among
irp
isol
distinct
genotyp
recognis
one
name
account
nine
isol
two
name
account
two
isol
respect
isol
irab
bore
integron
rang
size
bp
integron
name
bp
predomin
account
isol
isol
bore
combin
three
band
class
integron
present
irp
isol
rang
size
pb
conclus
resist
imipenem
baumannii
isol
higher
one
show
ps
aeruginosa
b
alway
combin
meropenem
resist
c
isol
also
resist
antibiot
test
pcrtype
show
major
baumannii
isol
belong
clone
ps
aeruginosa
sever
clone
identif
isol
bore
sever
class
integron
mean
rapid
spread
resist
gene
nosocomi
enviror
object
metallo
beta
lactamas
mediat
resist
increasingli
report
pseudomona
aeruginosa
especi
far
east
asian
countriesth
use
carbapenem
increas
last
year
intens
care
unit
icu
due
increas
preval
esbl
produc
strain
studi
perform
determin
preval
metallo
betalactamas
medit
mbl
carbapenem
resist
p
areuginosa
icu
patient
method
one
hundr
clinic
signific
isol
p
aeruginosa
icu
patient
taken
studi
suscept
anti
pseudomon
drug
includ
imipenem
aztronam
perform
disc
diffus
techniqu
minim
inhibitori
concentratrion
mic
imipenem
imipenemedta
combin
agar
dilut
detect
mbl
two
disc
method
imipenem
microgram
imipenem
edta
microgram
ceftazidim
microgram
ceftazidim
edta
microgram
use
result
fourteen
hundr
strain
mbl
produc
mic
imipenem
microgram
exhibit
decreas
mic
imipenem
edta
combin
signific
differ
inhibitori
zone
diamet
edta
compar
mbl
nonproduc
two
strain
exhibit
differ
ceftazidim
edta
anoth
imipenem
edta
one
isol
high
mic
valu
imipenem
mbl
produc
reflect
mechan
resist
mbl
produc
coresist
aminoglycosid
quinolon
conclus
mbl
mediat
carbapenem
resist
present
pseudomona
strain
icu
increas
use
carbapenem
critic
ill
patient
bound
increas
address
judici
use
carbapenem
continu
monitor
programm
use
ceftazidim
imipenem
edta
increas
sensit
mbl
detect
two
disc
method
produc
metallo
betalactamas
gener
intens
care
unit
southern
itali
background
object
metallobetalactamas
mbl
imp
vim
type
emerg
resist
determin
gramneg
nosocomi
pathogen
spread
consider
concern
antimicrobi
chemotherapi
due
carbapenemas
activ
resist
convent
betalactamas
inhibitor
although
epidemiolog
enzym
remain
larg
unknown
europ
imptyp
produc
report
less
frequent
vimtyp
produc
sporad
case
work
describ
outbreak
due
p
aeruginosa
produc
imptyp
mbl
intens
care
unit
italian
hospit
method
twentyseven
nonrepl
carbapenemresist
isol
p
aeruginosa
collect
inpati
intens
care
unit
giovanni
rotondo
hospit
southern
itali
period
octob
june
isol
lower
respiratori
tract
vitro
suscept
test
carri
microdilut
method
recommend
nccl
etest
broth
microdilut
method
epi
test
use
phenotyp
detect
mbl
produc
pcr
sequenc
carri
identifi
mbl
determin
puls
field
gel
electrophoresi
pfge
use
spei
restrict
enzym
perform
evalu
clonal
relationship
imipenemresist
clinic
isol
result
six
carbapenemresist
p
aeruginosa
isol
shown
produc
mbl
activ
epi
test
none
result
posit
etest
case
mbl
identifi
molecular
method
produc
resist
imipenem
meropenem
ceftazidim
retain
suscept
piperacillintazobactam
intermedi
suscept
aztreonam
pfge
analysi
show
mbl
produc
clonal
relat
suggest
clonal
spread
within
ward
remain
isol
belong
clonal
lineag
differ
produc
carbapenem
resist
due
mechan
mbl
product
conclus
best
knowledg
first
report
nosocomi
outbreak
caus
p
aeruginosa
produc
mbl
concern
phenotyp
detect
epi
test
could
correctli
detect
produc
etest
fail
reveal
object
aim
studi
investig
presenc
frequenc
occurr
acquir
metallobetalactamas
mbl
produc
pseudomona
aeruginosa
clinic
isol
hungari
method
screen
isol
edtainhibit
base
phenotyp
test
togeth
pcr
use
integron
blavim
blaimp
specif
primer
identifi
acquir
mblproduc
result
recent
isol
first
integronborn
mbl
gene
hungari
urin
sampl
greek
citizen
treat
august
budapest
dna
sequenc
reveal
presenc
class
integron
carri
three
gene
casett
oxatyp
lactamas
aminoglycosid
nacetyltransferas
type
mbl
gene
cassett
report
first
time
greec
observ
rais
possibl
p
aeruginosa
strain
origin
greec
import
hungari
human
carrier
octob
anoth
vimproduc
p
aeruginosa
strain
isol
southern
hungari
pcr
map
experi
suggest
strain
carri
class
integron
two
resist
gene
cassett
variabl
region
blavim
type
mbl
gene
cassett
right
upstream
conserv
sequenc
structur
diagram
two
integron
present
implic
possibl
phylogenet
relationship
conclus
isol
second
vimproduc
strain
appar
independ
case
repeat
appear
mbl
produc
clinic
isol
anticip
hungari
regular
screeningmonitor
system
set
prevent
wider
spread
resist
determin
suscept
miscellan
antimicrobi
agent
comparison
vitro
activ
gatifloxacin
moxifloxacin
trovafloxacin
clindamycin
clinic
signific
anaerob
k
aldridg
c
mander
broyl
new
orlean
usa
object
newer
fluoroquinolon
antimicrobi
increasingli
broadspectrum
potenc
activ
aerob
gramposit
gramneg
bacteria
anaerob
coverag
vari
wide
studi
perform
provid
contemporari
vitro
data
antianaerob
spectrum
three
quinolon
agent
two
respiratori
fluoroquinolon
gatifloxacin
gat
moxifloxacin
mxf
trovafloxacin
trv
previous
fdaapprov
fluoroquinolon
good
antianaerob
activ
limit
use
due
toxic
clindamycin
cli
longtim
use
antianaerob
lincosamid
ertapenem
ampicillin
amoxicillin
clavulan
cefuroxim
cefotaxim
ceftriaxon
imipenem
clarithromycin
chloramphenicol
tetracyclin
ciprofloxacin
levofloxacin
result
bacteri
timekil
demonstr
trend
ie
combin
exhibit
antagon
slower
kill
rate
member
pair
introduct
combin
betalactam
aminoglycosid
antibiot
broaden
spectrum
bacteri
coverag
often
achiev
synergist
inhibit
infect
pathogen
ertapenem
new
carbapenem
exhibit
activ
gramneg
gramposit
aerob
anaerob
object
provid
insight
optim
synergist
combin
ertapenem
aminoglycosid
materi
method
period
bacteri
strain
prospect
isol
patient
communityacquir
infect
vitro
activ
ertapenem
evalu
combin
amikacin
netilmicin
tobramycin
isol
includ
e
coli
k
pneumonia
p
mirabili
e
cloaca
methicillin
suscept
resist
coagulaseneg
staphylococci
aureu
mssa
mrsa
e
faecali
e
faecium
suscept
test
carri
accord
ncclsguidelin
combin
effect
determin
use
checkerboard
techniqu
result
ertapenem
exhibit
synergist
effect
strain
test
combin
amikacin
combin
gentamicin
notic
variat
differ
speci
test
combin
amikacin
mic
lgml
ertapenem
mic
lgml
found
synergist
enterococci
combin
ertapenem
mic
lgml
amikacin
mic
lgml
also
synergist
onethird
methicillinresist
cn
isol
hardli
synerg
speci
test
conclus
ertapenem
combin
aminoglycosid
antibiot
exhibit
mark
synergist
effect
certain
pathogen
includ
e
faecali
e
faecium
coagulaseneg
staphylococci
base
find
combin
therapi
could
benefici
treatment
infecti
diseas
caus
organ
qc
studi
evalu
perform
daptomycin
combin
daptomycincalcium
disk
etest
l
koeth
j
difranco
westlak
usa
background
vitro
suscept
test
daptomycin
cyclic
lipopeptid
antibiot
good
antimicrobi
activ
gramposit
bacteria
requir
presenc
calcium
ion
previou
studi
shown
agar
calcium
level
low
mcgml
adequ
disk
diffus
test
studi
perform
evalu
five
commerci
agar
determin
efficaci
disk
etest
strip
contain
combin
daptomycin
calcium
method
test
qc
strain
aureu
atcc
aureu
atcc
e
faecali
atcc
multipl
day
use
muellerhinton
agar
mha
bd
hardi
mast
isoton
agar
supplement
mcgml
calcium
ista
oxoid
isosensitest
agar
isoa
studi
strain
multipl
day
use
differ
lot
mha
bd
remel
thirtymicrogram
daptomycin
diskstablet
four
differ
manufactur
bbl
bd
oxoid
remel
mast
hardi
rosco
test
addit
mast
disk
mcg
calcium
etest
strip
daptomycin
daptomycin
mcgml
calcium
daptomycin
mcgml
calcium
evalu
calcium
test
media
perform
use
ion
select
electrod
result
mean
zone
diamet
mm
aureu
mean
etest
mic
mcgml
aureu
conclus
disk
contain
daptomycin
alon
bbl
rosco
mast
result
qc
valu
rang
media
except
isoa
except
ista
addit
mcg
calcium
daptomycin
mast
disk
rosco
tablet
provid
qc
result
within
rang
media
includ
isoa
two
differ
lot
bbl
affect
mic
zone
diamet
etest
contain
daptomycin
mcg
calcium
provid
optim
qc
result
late
increas
cell
count
mani
studi
refer
ie
relat
quantiti
betalactamas
quantit
proven
ampc
enzym
aim
work
evid
ie
p
stuartii
betalactam
due
quantiti
ampc
method
mic
betalactam
four
p
stuartii
strain
use
differ
initi
inocula
cfuml
determin
microdilut
procedur
cefotiam
mic
determin
use
differ
inocula
test
presenc
extracellular
signal
mic
determin
perform
condit
medium
accord
rather
et
al
j
bac
spontan
cefotiamresist
mutant
strain
select
mh
agar
plate
hydrolysi
cefotiam
broth
cultur
p
stuartii
initi
inocula
cfuml
bioassay
use
k
pneumonia
indic
organ
cefotiam
degrad
serial
dilut
crude
betalactamas
extract
p
stuartii
test
similarli
result
compar
use
comput
program
grafit
erithacu
softwar
base
linear
equat
result
strong
inoculum
effect
seen
test
p
stuartii
strain
cefotiam
mic
increas
microgml
increas
inoculum
p
stuartii
cfuml
quorum
sens
exclud
mic
influenc
use
condit
medium
cefotiam
select
resist
mutant
frequenc
hydrolysi
cefotiam
increas
cell
count
parallel
breakdown
antibiot
crude
enzym
extract
correl
mic
valu
conclus
small
increas
inoculum
size
convert
p
stuartii
betalactam
sensit
bacterium
resist
one
sole
due
cumul
betalactamas
product
cell
count
increas
select
mutant
quorum
sens
exclud
basi
inoculum
effect
object
dental
cement
use
adhes
materi
protect
seal
insul
tooth
fix
prosthodont
purpos
studi
examin
feasibl
ad
antimicrobi
activ
zinc
polycarboxyl
cement
durelon
addit
antisept
chlorhexidin
glucon
chx
method
total
teeth
site
sampl
evalu
site
randomli
assign
either
test
group
chx
zinc
polycarboxyl
cement
control
group
convent
zinc
polycarboxyl
cement
test
group
chx
use
instead
water
bacteriolog
evalu
done
begin
week
restor
cement
subgingiv
microbiolog
sampl
obtain
insert
steril
paper
point
gingiv
sulcu
subjac
restor
standardis
paper
strip
place
six
locat
restor
individu
tooth
isol
quadrant
salivari
contamin
bridg
made
porcelain
cement
zincpoli
carboxyl
phosphat
follow
standard
procedur
sampl
cultur
aerob
anaerob
convent
method
isol
bacteria
identifi
use
api
autom
system
biomerieux
franc
result
restor
zinc
polycarboxyl
cement
result
chang
associ
microflora
alter
flora
resembl
way
observ
adult
chronic
periodont
increas
proport
gramneg
anaerob
rod
especi
provotella
intermedia
fusobacterium
nucleatum
observ
restor
chx
zinc
polycarboxyl
cement
result
rel
chang
associ
subgingiv
microflora
rel
preexperiment
find
conclus
addit
chx
subscanti
increas
antimicrobi
action
zincpolycarboxyl
lute
agent
without
interf
physic
properti
